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Abstract 
 
 
Mesenchymal stromal cells (MSC) from the umbilical cord (UC) are a promising tool for 
regenerative medicine due to their easy acquisition, high expansion potential and the ability to 
differentiate into multiple lineages. In particular, the capacity for osteogenic differentiation 
makes them of great interest for clinical application in bone repair.  
In this work, 51 MSC lines were isolated from different parts of 26 UC and successfully 
expanded in fetal bovine serum (FBS)-containing medium. These cells complied with the criteria 
for MSC classification as they were adherent to plastic, capable of multilineage differentiation, 
and expressed CD73, CD90, CD44 and CD105 while lacking hematopoietc and endothelial 
markers. Differentiation of the different MSC lines along the osteogenic lineage was variable 
depending mostly on the tissue source and isolation method. Moreover, osteogenic 
differentiation could be modulated by selecting for cells with high expression levels of CD105 
(Endoglin) or by the co-culture of MSCs with different osteogenic potential. With the aim of 
establishing xeno-free clinically compatible culture conditions, StemPro MSCs serum free 
medium (SP-MSC SFM), human platelet lysate (in medium or in plasma), human plasma and 
AB serum (hABS) were tested. We have observed that only hABS supplemented medium could 
efficiently sustain MSC expansion, morphology, immunophenotype and multi-lineage 
differentiation similarly to FBS-containing medium. Finally, preliminary data indicates that frozen 
immunologically inert amniotic membrane is a suitable substrate for osteogenic differentiation of 
MSCs and, therefore, a promising scaffold for producing an osseous matrix for application in 
regenerative medicine. 
 
Keywords: Amniotic Membrane; Endoglin; human AB serum; Mesenchymal Stromal Cells; 
Osteogenic Differentiation; Umbilical Cord.  
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Sumário 
 
A medicina regenerativa é uma área em grande expansão que tenta ultrapassar a 
escassez e curto tempo de vida dos órgãos e tecidos doados para transplantação e os 
problemas decorrentes da histocompatibilidade (Chai e Leong 2007). Para tal, células 
estaminais são expandidas e diferenciadas in vitro num sistema de suporte criado 
artificialmente. As células estaminais têm o potencial de se auto-renovarem por divisão mitótica 
mantendo a capacidade de se diferenciarem em vários tipos celulares e deste modo de 
repovoarem um tecido in vivo. As células mesenquimais do estroma (MSCs, “mesenchymal 
stromal cells”) representam uma população de células estaminais adultas multipotentes de 
grande interesse de estudo na área da regeneração de tecidos (Kode et al., 2009). Estas 
células foram inicialmente identificadas como uma população rara de células estaminais não 
hematopoiéticas presente na medula óssea (Friedenstein et al., 1966; Friedenstein et al., 1987; 
Kode et al., 2009; Owen e Friedenstein, 1988). Contudo, tem vindo a ser descrito o isolamento 
destas células de variados tecidos, entre eles o cordão umbilical humano (UC, “umbilical cord”) 
(Lu et al., 2006; Nekanti et al., 2010; Shetty et al., 2010). O UC é constituído por duas artérias, 
uma veia, e uma matriz circundante de tecido conectivo designada por geleia de Wharton (WJ 
“Wharton’s jelly”), composta por células com morfologia fibroblástica e alguns mastócitos numa 
substância amorfa rica em proteoglicanos, principalmente ácido hialurónico (Can e 
Karahuseyinoglu, 2007). MSCs foram já isoladas a partir de todos estes constituintes do UC e 
constituem uma ferramenta promissora em medicina regenerativa, devido à sua fácil aquisição, 
elevado potencial de expansão e capacidade de se diferenciar em várias linhagens, 
nomeadamente osteogénica, adipogénica e condrogénica. Em particular, a sua capacidade de 
diferenciação osteogénica é de grande interesse para a aplicação clínica destas células em 
reparação óssea. 
Neste trabalho MSCs foram isoladas de diferentes partes de 26 UCs tendo 51 linhas 
celulares sido obtidas. Em particular, foram isoladas células da geleia de Wharton periférica 
(pWJ) e total (tWJ), apenas dos vasos (V-UC), e de todo o cordão (W-UC). Para isto 
aperfeiçoámos um método composto por uma fragmentação mecânica da WJ, V-UC e W-UC 
em pequenos pedaços seguida de uma digestão enzimática de 3 a 4 horas com colagenase e 
hialuronidase, deste modo obtendo um bom equilíbrio entre a dissociação do tecido e a 
viabilidade celular. Para a obtenção de tWJ-UC e V-UC foi necessário efectuar uma digestão 
enzimática inicial da parte interna do cordão para permitir a remoção dos vasos. As células 
isoladas foram então expandidas num meio de cultura composto pelo meio basal Dulbecco's 
Modiﬁed Eagle's Medium F12 (DMEM-F12), glutamina e soro fetal bovino (FBS). Estas células 
preencheram os critérios de classificação para MSCs estabelecidos pela Sociedade 
Internacional para a Terapia Celular (ISCT), uma vez que: eram aderentes ao plástico; auto-
renovaram-se em cultura ao longo de várias passagens; expressam os marcadores de 
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superfície específicos CD73, CD90, CD44 e CD105, e não marcadores hematopoiéticos nem 
vasculares como CD45 e CD34; e foram capazes de se diferenciar nas linhagens osteogénica, 
adipogénica e condrogénica.  
Com o objectivo de obter condições de cultura compatíveis com uma aplicação clinica, 
ou seja sem produtos animais tais como o FBS, foram testados como candidatos o meio de 
cultura comercial StemPro (SP-MSC SFM), lisado de plaquetas humanas (ressuspendidas em 
meio- hPL ou em plasma-hPLP), plasma humano (hP) e soro AB humano (hABS). Um meio de 
cultura apropriado para esta aplicação, deverá ser capaz de sustentar a expansão de MSCs 
mantendo a sua morfologia, fenótipo e o potencial de diferenciação em diferentes linhagens. 
Neste estudo, o meio de cultura com hPLP, hPL ou hP apenas permitiu a sobrevivência das 
MSCs por 3 passagens, ainda que usando placas de cultura revestidas com fibronectina 
humana e adicionado 250µM de ácido ascórbico (asc), condições que deveriam facilitar a 
expansão de MSCs (Choi KM et al., 2008; Potdar e d’Sousa, 2010), como foi possível verificar 
no meio com FBS. 
 No meio de cultura SP-MSC SFM e no meio suplementado com hSAB foi possível 
expandir as células durante pelo menos 8 passagens. Contudo, em SP-MSC SFM as células 
sofreram algumas alterações morfológicas e uma diminuição da expressão de CD105 ao longo 
do tempo em cultura. Por seu lado, MSCs expandidas em hSAB (um pool de soro humano AB 
alogénico) exibiram o comportamento desejado uma vez que nem a sua morfologia nem o 
imunofenótipo foi alterado quando comparado com células em meio com FBS. De grande 
importância foi também a observação que, enquanto em MSCs expandidas em SP-MSC SFM 
houve uma redução na capacidade de diferenciação osteogénica das células, em meio com 
hSAB esta capacidade foi mantida. Bons resultados no uso de hSAB como suplemento do 
meio de cultura de MSCs tinham já sido documentados em outros estudos (Yamaguchi et al., 
2002; Kocaoermer, Kern e Kluter et al., 2007). 
Para a análise do potencial osteogénico das MSCs foram testados diversos meios 
basais de cultura (com diferentes concentrações de glucose e aminoácidos) e combinações 
dos osteoindutores ácido ascórbico, dexametasona e β-glicerofosfato. No entanto, observámos 
que melhores resultados foram obtidos com o meio de cultura comercial MesenCult osteogenic 
stimulatory kit. A diferenciação osteogénica das células foi avaliada através da análise da 
expressão génica, imunofenotipagem por citometria de fluxo, marcação para a actividade da 
fosfatase alcalina (AP), característica da fase de deposição de matriz orgânica 
(aproximadamente aos 14 dias de diferenciação), e numa fase mais tardia (de mineralização) 
pela deposição de cálcio detectada com vermelho de Alizarina ou marcação von Kossa. Assim, 
foi possível observar que durante a osteogénese há uma diminuição inicial da expressão de 
CD105, CD73 e de CD90 (tanto RNA como proteína), seguida do aparecimento de fosfatase 
alcalina e osteocalcina, e finalmente um aumento gradual da deposição de cálcio a partir dos 
21 dias de diferenciação. 
Neste estudo foi observada uma grande variabilidade na capacidade de diferenciação 
das diferentes linhas de MSCs obtidas. Esta variabilidade parece estar de alguma forma 
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relacionada com o tecido e método de isolamento utilizado. No entanto, outros factores como a 
densidade celular no início da cultura, o nível de expressão de CD105 e a interacção entre 
células parecem também ter uma importante influência na aptidão osteogénica das MSCs 
 
Em diversos aspectos deste estudo o antigénio CD105, pareceu ter um papel 
relevante, uma vez que a diminuição da sua expressão em SP-MSC-SFM parece inibir a 
osteogenése, e as células seleccionadas para elevados níveis desta proteína provocam o 
aumento de diferenciação das MSCs. O CD105, ou Endoglina, é uma glicoproteina membranar 
de tipo I que faz parte do complexo do receptor TGF-β (Barbara et al., 1999; Blanco et al., 
2005). Assim, a regulação dos níveis de expressão de CD105 pode estar relacionada com a 
modelação da sinalização em resposta ao TGF-β e esta pode determinar aspectos cruciais da 
diferenciação osteogénica. Este aspecto deverá ser alvo de estudos futuros. 
Outro aspecto importante da diferenciação é a matriz ou substrato onde sobre a qual se 
encontram as células (Salasznyk et al., 2004; Cool e Nurcombe, 2005; Chastain et al.,2006). 
Neste estudo propusemos a utilização de membrana amniótica (AM “Amniotic membrane”) 
como um substrato adequado para promover a diferenciação osteogénica de MSCs, o que 
ajudaria a ultrapassar a necessidade de dissociação das células e disrupção de uma matriz 
óssea para transplantação num paciente. Os nossos dados preliminares indicam que a AM 
congelada imunologicamente inerte é um substrato adequado para diferenciação osteogénica 
de MSCs, apesar de dificuldades em prevenir o enrolamento e enrugamento da membrana 
durante a diferenciação e de esta diferenciação ser menos eficiente que a de células cultivadas 
em plástico. Um outro aspecto interessante foi a detecção de um nível basal de AP em MSCs 
sobre AM em meio de expansão. Isto sugere que a AM tem propriedades intrínsecas que lhe 
permitem induzir osteogénese, como sejam factores de crescimento presentes na AM (Koizumi 
et al., 2000; Valladares et al., 2010). Apesar de estudos adicionais serem necessários de modo 
a melhorar as condições de cultura das MSCs na AM, este parece ser um substrato promissor 
para a produção de uma matriz óssea para aplicação em medicina regenerativa. 
 
Palavras-chave: Células Mesênquimais do Estroma; Cordão Umbilical; Diferenciação 
Osteogénica; Endoglina; Membrana Amniotica; Soro AB Humano.  
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Aims of the thesis 
  
In this study, with the propose improve the knowledge of the biology of UC-MSCs for 
future application in bone tissue regeneration, we aim to establish culture conditions for the 
expansion and differentiation of UC-MSCs on amniotic membrane, in order to produce a bone 
matrix for application in regenerative medicine. With this purpose, the following objectives were 
defined:  
1.  To establish an efficient technique for the isolation of MSCs from different parts of 
umbilical cord (Wharton’s jelly, vessels and whole cord). For this, both mechanical and 
enzymatic methods (combinations of collagenase, hyaluronidase and trypsin) were tested in 
search for the most reliable and efficient one.  
2.  To determine appropriate culture conditions for the expansion and differentiation of 
UC-MSC, compatible with a clinical application. To accomplish this, we tried to replace the 
animal and chemically undefined media components. A commercially available serum-free 
medium containing the growth factors PDGF-BB, bFGF and TGF-β1(StemPro MSC serum free 
medium), human platelet lysate (in medium and plasma), human plasma and human AB serum 
were tested and the cells grown in this medium were compared to FBS-containing standard 
medium.   
3.  To characterise UC-derived MSCs in expansion and differentiation conditions. With 
this purpose, the cell proliferation, gene expression and MSC surface phenotype were assessed 
for cells grown in expansion conditions (for various periods of time in culture) and after induction 
of differentiation. Moreover, some culture conditions and characteristics of these cells that could 
be related to or help predict the osteogenic potential were analysed.  
 
4.  To test the amniotic membrane as substrate for the production of a bone matrix. This 
step aimed at finding a safe and quickly adapted vehicle for transplantation.   
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1. Introduction 
 
1.1. Mesenchymal Stromal Cells (MSCs) 
 
Over the years, much progress has been made in the use of biological resources to 
reconstruct, replace, or repair diseased cells, tissues and organs in order to improve the quality 
of life of millions of people around the world (Chai and Leong, 2007; Lutolf and Blau, 2009). The 
emerging field of Regenerative Medicine attempts to overcome the shortage in donor organs 
and tissues for transplantation (Chai and Leong 2007) by growing and differentiating cells 
outside the patient in artificially-created support systems.  
In the human body an intrinsic stem cell-based regeneration and repair system that 
uses stem cells is believed to be found in almost in every tissue type (Bajada et al., 2008). Stem 
cells have the potential to self-renew by mitotic division while maintaining the ability to 
differentiate into many cell types, therefore being able to repopulate a tissue in vivo. There are 
stem cells of several types and origins. Pluripotent stem cells can give rise to all cell types in a 
body and typically include the following (Xu et al., 2008): embryonic stem cells, derived from the 
inner cell mass of pre-implantation embryos; epiblast stem cells derived from post-implantation 
epiblast-stage embryos; germ line stem cells and induced pluripotent stem (iPS) cells obtained 
by genetic manipulation from somatic cells. Adult stem cells have a more restricted potential 
and generally give rise only to the differentiated lineages of the tissue in which they reside, 
being thus referred to as multipotent or unipotent (Watt and Driskell, 2010).  
  
Mesenchymal stromal cells (MSCs) represent a multipotent adult stem cell population 
(Kode et al., 2009) that has been shown to be capable of differentiating in vitro and in vivo along 
multiple lineages including those that give rise to bone, cartilage, cardiac and skeletal muscle, 
neural cells, tendon, adipose, and connective tissue (Nekanti et al., 2010), depending on the 
surrounding environment. These mesenchymal stromal cells, whose existence was first 
suggested by Cohnheim in 1867, were later identified in the bone marrow (BM) by Friedenstein 
and colleagues as a rare population of adherent non-hematopoietic stem cells (Friedenstein et 
al., 1966; Friedenstein et al., 1987; Kode et al., 2009; Owen and Friedenstein, 1988). It was 
subsequently shown that they can actually be isolated from a variety of other tissues including 
adipose tissue (Zuk et al., 2002), skeletal muscle (Young et al., 2001), blood (Zvaifler et al., 
2000), dental pulp (Gronthos et al., 2000), skin (Lorenz et al.,2008), amniotic fluid (Tsai et al., 
2004), umbilical cord  blood (Lu et al.,2006) and stroma (McElreavey et al., 1991; Romanov et 
al., 2003; Seshareddy et al. 2008; Troyer and Weiss, 2008; Wang et al, 2004), among others 
(Chamberlain et al., 2007; da Silva Meirelles et al., 2006; Musina et al., 2005; Riekstina et al., 
2009).    
 
Several studies have focused on the characterization of MSCs, revealing important 
aspects of their biology and defining molecular markers that allow their identification. As the 
defining characteristics of MSCs are inconsistent among investigators, The International Society 
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for Cellular Therapy (ISCT) has proposed three major criteria to define human MSCs (Table 1) : 
(1) adherence to plastic, (2) a specific surface phenotype, and (3) the ability to differentiate in 
vitro into cells of the osteoblastic, adipogenic and chondrogenic lineages (Dominici et al., 2006).    
 
       Table1: Summary of criteria to identify MSCs (reproduced from Dominici et al., 2006) 
1.  Adherence to plastic in standard culture conditions  
2.  Phenotype            Positive (≥95% positive)             Negative (≤2% positive)  
                                               
                                                                           
 
 
3.  In vitro differentiation: osteoblasts, adipocytes, chondroblasts  
(demonstrated by staining of in vitro cell culture) 
 
MSCs express a large number of adhesion molecules, extracellular matrix proteins, 
cytokines and growth factors, which are associated  with their function and interactions within 
the various tissues where they are present (Bobis et al., 2006). These cells do not have a 
unique phenotypic marker but they express a characteristic array of surface proteins including 
CD73 (5'-nucleotidase), CD90 (Thy-1 cell surface antigen) and the matrix receptors CD44 and 
CD105 (Endoglin) (Bobis et al., 2006; Chamberlain et al., 2007). MSCs also express adhesion-
related antigens  (integrins  αvβ3,  αvβ5, integrin subunit  α4,  α5 and  β1, intracellular adhesion 
molecule-1 (ICAM-1) and CD44H), and produce cytokines, chemokines and growth factors 
(interleukin (IL)-6, IL-7, IL-8, IL-11, IL-12, IL-14, IL-15, leukemia inhibitory factor, granulocyte 
colony stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-
CSF), stem cell factor, macrophage colony-stimulating factor (M-CSF) and fms-like tyrosine 
kinase-3 ligand (flk-3L)) (Chamberlain et al., 2007; Bobis et al., 2006; Fox et al., 2007). 
Additionally, they also express cytokine (IL-1R, IL-3R, IL-4R, IL-6R and IL-7R) and chemokine 
receptors (CCR1, CCR4, CCR7, CXCR5 and CCR10), which may be involved in the directed 
migration of MSCs for tissue repair (Fox et al., 2007; Sordi, 2009). On the other hand, MSCs 
lack the endothelial and hematopoietic stem cell marker CD34, the pan-leukocyte marker CD45, 
the endothelial markers von Willebrand factor and CD31 (platelet/endothelial cell adhesion 
molecule), and the monocyte marker CD14 (monocyte differentiation antigen) (Bobis et al., 
2006; Chamberlain et al., 2007; Dominici et al., 2006). 
 
Depending on the tissue source, method of isolation, culture conditions and species 
differences, MSCs present variable morphology, expression levels of many of the markers 
mentioned, and proliferative and differentiation potentials (Barry et al., 2004; Musina et al., 
2005; Riekstina et al., 2009). Human MSC cultures are morphologically heterogeneous ranging 
from narrow spindle-shaped to large and flattened polygonal cells and some cuboidal one in 
confluent cultures, even though there is a predominance of the fibroblastic morphology 
(Javazon et al., 2004; Chamberlain et al., 2007).  
CD45 
CD34 
CD14 or CD11b 
CD79α or CD19 
HLA-DR 
CD105 
CD73 
CD90 
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As previously mentioned, MSCs are able to differentiate in vitro and in vivo (Figure 1), 
mostly along, but not restricted to, the osteogenic, chondrogenic and adipogenic lineages 
(Chamberlain et al., 2007; Pittenger et al., 1999; Kode et al., 2009). Additionally, MSCs have 
been reported to home to areas of tissue injury, where they set-up a regenerative 
microenvironment and participate in tissue repair (Chamberlain et al., 2007; Fox et al., 2007; 
Sordi, 2009). MSC homing follows a mechanism similar to the one of leukocyte trafficking, even 
though not involving exactly the same cytokines, chemokines and adhesion molecules 
(Chamberlain et al., 2007; Fox et al., 2007). MSCs have also been described to possess anti-
inflammatory and immunomodulatory properties that can affect multiple arms of the immune 
system (Chamberlain et al., 2007; Kode et al., 2009; Nauta and Fibe, 2007). These features 
increase the clinical interest in these cells, particularly in regenerative medicine and for 
tolerance induction in allogeneic transplantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Differentiation potential of MSCs. Pictorial representation of MSCs expanded in vitro can be 
induced to differentiate into several lineages following exposure to specific differentiation factors. Image 
from Kode et al., Cytotherapy 2009, 11:377-91.   
 
 
1.2. The Umbilical Cord as a stem cell source 
 
Different MSC tissue sources may be especially suited for specific clinical applications 
as culture-expanded MSCs exhibit heterogeneity in their differentiation potential (Chamberlain 
et al., 2007; Nekanti et al., 2010). Although BM-MSCs have been most commonly used in 
differentiation studies, they are limited by the fact that the collection process is invasive, the 
number of cells obtained is limited and the quality of the cells in terms of proliferative and 
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differentiation abilities decreases in aged donors (Kim et al., 2010).Therefore, in recent years 
there has been a lot of interest in the search for novel stem cell sources for specific clinical 
applications and the umbilical cord is one such source (Nekanti et al., 2010).  
 
The Umbilical Cord (UC) constitutes the link between mother and fetus during 
pregnancy (Can and Karahuseyinoglu, 2007) and is usually discarded after delivery, thus 
providing an abundant stem cells source in a noninvasive and ethical way (Nekanti et al., 2010). 
The UC inner architecture (Figure 2) is composed of a set of two arteries (UCA) and one vein 
(UCV) and a surrounding matrix of mucous connective tissue, first described by Thomas 
Wharton in 1656, and thus named Wharton’s Jelly (WJ) (Can and Karahuseyinoglu, 2007). The 
WJ, which acts as a protective tissue of the UC vessels, comprises specialized fibroblast-like 
cells and occasional mast cells embedded in an amorphous ground substance rich in 
proteoglycans, mainly hyaluronic acid (Can and Karahuseyinoglu, 2007). 
 
Figure 2. Pictorial representation of different regions of within the umbilical cord. The cord is divided 
in 5 compartments: 1. umbilical cord blood, 2. umbilical vein subendothelium, 3. perivascular, 4. 
intervascular and 5. subamnion. Wharton’s jelly includes zones 3 through 5. Image from Troyer and Weiss. 
Stem Cells 2008, 26(3):591-9.    
 
MSCs have been successfully isolated from UC WJ explants (Wang et al., 2004; 
Friedman et al., 2007; Karahuseyinoglu et al., 2007; Chen et al., 2009; Ishige et al., 2009; Fong 
et al., 2011; Hsieh et al., 2010;), UC vascular endothelial surface (Romanov et al., 2003; 
Sarugaser, et al., 2005;), UC vessels (Panepucci et al 2004; Ishige et al., 2009) and UC blood 
(Secco et al., 2009; Martins et al., 2009; Chang et al., 2006; Zeddou et al., 2010). They can also 
be obtained by processing the whole UC tissue (Zeddou et al., 2010, Secco et al., 2009). Two 
main methods have been described for isolating UC-MSCs: exclusively mechanical (Mitchell et 
al., 2003; Chen et al., 2009; Ishige et al., 2009), or the combination of mechanical and one or 
more enzymatic steps (Wang et al., 2004; Seshareddy et al. 2008; Karahuseyinoglu et al., 
2007; Fong et al., 2007; Hsieh et al., 2010). Regarding UC blood (UCB), some researchers 
have successfully isolated MSCs from this source although there is great controversy in the 
literature regarding its efficiency and feasibility (Kim et al., 2010; Stronk et al., 2007; Martins et 
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al., 2009; Choi et al., 2009). Despite the low proportion of MSC obtained from UCB when 
compared to BM-MSCs, UCB-MSCs have been shown to exhibit a better performance in culture 
(Bieback et al., 2004; Yang et al., 2004; Sanchez-Ramos 2006). Nevertheless, more recently, 
Secco et al. (2008) have showed that UC stroma is much richer in MSCs than UCB. UC stroma 
MSCs have been reported to have several advantages compared to UCB MSCs and BM-MSCs 
(Troyer et al., 2008) such as a higher frequency of colony forming units (CFUs), which can be 
due to the expression of telomerase by UC stroma cells (Mitchell et al., 2003), and a lower 
immunogenicity (Weiss et al., 2008).  Comparing UC stroma, UCA and UCV it was not 
conclusive which one was a better source (Ishige et al., 2009). Nevertheless, UCV cells appear 
to have a higher frequency of CFUs than UC and UCA. All these three tissue sources seem to 
have the ability to differentiate into chondrocytes, adipocytes and osteoblasts, but UC stroma 
was described by Ishige and colleagues as the one with the least osteogenic potential and UCA 
with the greatest (Ishige et al., 2009).          
When compared with MSCs from BM, UC stroma and UC perivascular MSCs seem to 
proliferate better than the ones from the BM (Baksh et al., 2007; Hsieh et al., 2010). Regarding 
differentiation, UC perivascular MSCs were described to differentiate into osteoblasts more 
rapidly than BM-MSCs (Baskh et al., 2007). When compared to BM-MSCs, UC stroma cells 
were reported to be more committed to angiogenesis while BM-MSC preferentially undergo 
osteogenesis (Hsieh et al., 2010; Panepucci et al., 2004; Chen et al., 2009).          
 
1.3. Clinical application of MSCs 
 
As previously mentioned, thanks to their easy attainment, extensive in vitro proliferation,  
wide-range of differentiation potential, homing ability and immunological properties, MSCs are a 
promising tool in cell therapy, tolerance induction in allogeneic transplantation, and regenerative 
medicine (Bernardo et al., 2011; Kode et al., 2009; Krampera et al., 2006). For their application 
in regenerative medicine, stem cells must follow several criteria. These include: production of 
substantial numbers of cells, harvesting using a minimally invasive procedure, cell multilineage 
differentiation in a regulated and reproducible manner, safe and effective transplantation to 
either an autologous or allogeneic host, and manufacture in accordance with current Good 
Manufacturing Practice guidelines (Gimble et al., 2007).  
Despite being a great promise for the future, until this date, there are few examples of 
clinical applicability of stem cells in the field of regenerative medicine. This is due to (Bajada et 
al., 2008): difficulties with extensive in vitro cell expansion; cell apoptosis following implantation; 
problems with vascularisation of the growing tissue; problems in finding viable scaffold 
biomaterials; high costs associated with prolonged maintenance of the cells in culture; and 
moral concerns or ethical issues that delay the transition for clinical use. 
 
The increasing interest in the use of MSCs in tissue regeneration and the treatment of 
immune disorders leads to the need of developing production processes that are in accordance 
with Good Manufacturing Practices (GMPs). These regulations have the aim of ensuring the 
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delivery of safe, reproducible, and effective products (Kode et al., 2009; Sensebé et al., 2011). 
And therefore cover all aspects of manufacturing (Sensebé et al., 2011). In Europe, MSCs are 
considered advanced therapy medicinal products (ATMPs), as defined by the European 
Regulation (Sensebé et al., 2011).  
 
 
Regarding the procedures for the production of MCSs for therapeutical purposes, the 
main parameters to be considered are the sources and collection methods, extent of 
manipulation (preferentially in closed systems), methods for MSC enrichment, purity, culture 
medium, cell plating density, passaging, and time in culture, as all these may affect the quality 
of MSCs (Bourin et al., 2008; Sensebé et al., 2010; Sensebé et al., 2011).  For these reasons, 
finding the optimal culture conditions has been of great interest to researchers.  
In particular, the culture medium is crucial for the efficacy and safety of MSC cultures. 
The media used in culture processes should maintain the phenotype, genotypic stability, 
proliferation and functions of MSCs during multiple passages. Consensus is lacking on the ideal 
medium for MSC expansion, but the standard culture condition has been a basal medium 
supplemented with animal serum, typically at a concentration of 10%, with or without added 
growth factors. Numerous types of basal media have been tested, and one of the main issues, 
the glucose content, remains controversial as its effect might be dependent on the cell source or 
differ between short-term and long-term culture (Sotiropoulou et al., 2006; Weil et al., 2009; Pal 
et al., 2009; Nekanti et al., 2010). Besides glucose, various other factors are important in the 
culture medium such as additional aminoacids, vitamins, inorganic salts, etc. (Nekanti et al., 
2010).  
Regarding the serum, Fetal Bovine Serum (FBS) is the most commonly and 
successfully used. However, the animal and poorly defined nature of FBS, the batch to batch 
variability, the risk of sensitisation due to FBS proteins retained in the cytoplasm of MSCs, and 
the fact that it is a possible source of bovine prion, viral and zoonose contamination 
(Schallmoser et al., 2007; Chase et al., 2010) make it an undesirable component of the culture 
medium. Despite these hindrances, FBS can be used for GMP production of MSCs as long as it 
is carefully tested before use and a Transportation Security Administration certificate is obtained 
to ensure safety in terms of the risk of infectious disease transmission (Sensebé et al., 2011). 
Nevertheless, there still is an increased risk associated with the use of FBS as reported by 
Selvaggi and collegues that when it was infused into patients lymphocytes expanded in FBS, 
these patients developed hypersensitivity reactions (Selvaggi et al., 1997).  
Nevertheless, there still is an increased risk associated with the use of FBS and some 
examples have previously been reported: alteration of cell behaviour and morphology in the 
presence of FBS in culture (Hung and Young 2006) and the development of hypersensitivity, 
malignant ventricular arrhythmias and in some cases sudden death in patients who received 
cells cultivated in FBS (Selvaggi et al., 1997; Chachques et al., 2004). Therefore, safety 
requirements imply replacing FBS with more secure products such as human components or a 
fully defined serum-free medium.  
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Replacing FBS with human or humanised components is one of the most challenging 
aspects of GMP translation in MSC production. The reduced efficiency of animal serum-free 
culture conditions may be overcome by supplementing the medium with growth factors and 
cytokines that activate signalling pathways crucial for MSC expansion while preserving their 
differentiation potential. Some of the growth factors already reported to have an essential role 
are the platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming 
growth factor (TGF)-β, insulin-like growth factor (IGF), and fibroblast growth factor (FGF)-2 
(Kilian et al., 2004; Choi SC et al., 2008; Ng et al., 2008; Chase et al., 2010; Tamama et al., 
2010). However, the complete growth factor requirements for MSC expansion are still unknown. 
In other studies, human serum (hS), or in particular human AB serum (hABS), plasma (hP), 
platelet lysates (hPL) or thrombin-activated platelet releasate in plasma (tPRP) have also been 
tested as FBS replacements (Kocaoemer et al., 2007; Bieback et al., 2009; Doucet et al., 2005; 
Shahdadfar et al., 2005; Schallmoser et al., 2007; Strunk et al., 2007; Avanzini et al., 2009; 
Turnovcova et al., 2009). The most promising and most often used is the platelet lysate, human 
plasma enriched by growth factors released from platelets. Platelet granules contain many 
growth factor proteins, including PDGF, fibroblast growth factor (FGF), IGF, TGF-β, platelet 
factor 4 (PF-4), and platelet-derived epidermal growth factor (PDEGF) (van den Dolder et al., 
2006;  Doucet et al., 2005; Chevallier et al., 2010). These growth factors, which are released 
from platelet concentrates when subjected to freeze-thaw cycles, have been shown to 
successfully support MSC expansion in vitro (Doucet et al., 2005; Schallmoser et al., 2007; 
Müller et al., 2006). Regarding human serum, its successful use seems to be restricted to 
autologous serum (Yamamoto et al. 2003; Lin et al., 2005; Shahdadfar et al., 2005; Mizuno et 
al., 2006), as allogeneic serum has produced contradictory results (Shahdadfar et al., 2005; 
Kocaoemer et al., 2007). However, pooled human allogeneic serum would provide a more 
abundant and immediately available source and would thus be a more advantageous alternative 
than autologous serum to expand MSCs for clinical application (Kocaoemer et al., 2007; 
Mannello et al., 2006). Nevertheless, there still is a need to test the proliferation and 
functionality of MSCs grown in these media.  
 
   
1.4. MSC multi-lineage differentiation  
 
As defined by the ISCT, to be classified as MSCs, the cells must differentiate into 
osteoblasts, chondrocytes and adipocytes under appropriated conditions.   
One of the most promising applications of MSCs in regenerative medicine is in bone 
repair (Krampera et al., 2006; Sensebé et al., 2010). The bone is a mesenchymal-derived tissue 
with various functions, including mechanical, metabolic and protective of vital organs (Clarke, 
2008; Duplomb et al., 2007). It is composed of an organic mineralised connective tissue with 
two main cell lineages: osteoblasts and osteoclasts (Duplomb et al., 2007). Osteoblasts are 
mesenchymal-derived cells specialised in the production of organic matrix and in the 
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mineralisation process (Jayakumar and Di Silvio, 2010). Osteoblast cells can progressively 
differentiate into osteocytes and these two cell types together constitute a cellular network that 
allows the communication between bone surface and mineral matrix (Clarke, 2008; Jayakumar 
and Di Silvio, 2010). Bone resorption is controlled by osteoclasts, which differentiate from 
hematopoietic precursors (Clarke, 2008; Duplomb et al., 2007; Jayakumar and Di Silvio, 2010). 
A balance between osseous tissue formation by osteoblasts and bone resorption by osteoclasts 
is required for bone homeostasis (Clarke, 2008; Jethva et al., 2009). The osseous organic 
matrix (the osteoid), produced by the osteoblasts, is mainly composed of collagen type I and II, 
fibronectin and growth factors. This matrix subsequently gets mineralised forming an inorganic 
matrix that consists of hydroxyapatite crystals (Clarke, 2008).   
A good understanding of the osteoblast differentiation process is important for two main 
reasons: to allow the application of osteoblast committed-cells in regenerative medicine, and to 
identify new key genes that could be deregulated during pathological processes (bone tumour, 
osteoporosis, etc). Osteoblast differentiation is controlled by a hierarchy of transcription factors 
that are expressed in a defined temporal sequence, both in vivo and in vitro (Franceschi et al., 
2009; Komori, 2006, Kalajzic et al., 2005) (Figure 3). During embryonic development the 
transcription factor Runx2/Cbfa1 (core binding factor  α1) first appears with the formation of 
mesenchymal condensations in areas destined to become bone, and persists through 
subsequent stages of bone formation (Franceschi et al., 2009). Osterix (Osx) is a zinc finger-
containing transcription factor, which is important for the commitment of osteoblast progenitors 
into the osteoblast lineage (Nakashima et al., 2002). In the absence of Osx, no cortical bone 
and no bone trabeculae were formed through either intramembranous or endochondral 
ossification (Nakashima et al., 2002). Activating transcription factor 4 (Atf4) appears to be 
important in later phases, and is expressed in mature osteoblasts (Franceschi et al., 2009). The 
activation of these transcription factors is accompanied by the expression of other specific 
proteins, which can be used as markers to identify the differentiation stage of osteoblasts 
(Kalajzic et al., 2005; Franceschi et al., 2009). Type I collagen and osteonectin (a calcium-
binding glycoprotein) start being transcribed at the phase of bone matrix formation, following 
Atf4 activation. When the mineralization phase is initiated a large increase in osteocalcin (bone 
gamma-carboxyglutamic acid-containing protein) expression is observed (Franceschi et al., 
2009). Additionally, bone sialoprotein (BSP) and alkaline phosphatase (AP) have also been 
described to be involved in the mineralisation process (Fauran-Clavel and Oustrin, 1986; 
Franceschi et al., 2009). Osteogenic assessement is usually performed by staining for AP 
activity, and in a later phase by Alizarin Red or von Kossa techniques that specifically detect for 
calcium deposition.  
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Figure 3. Hierarchy of transcription factors that control osteogenic lineage. Adapted from Franceschi 
et al. Cell Tissues Organs 2009, 189:144-152. 
 
The standard method to induce osteogenic differentiation has been to add combinations 
of dexamethasone (dex), β-glycerophosphate (β-GP), ascorbic acid (asc), and occasionally 
1α,25-dihydroxy vitamin D3, to the culture medium in the presence of FBS (Jaiswal et al., 1997; 
Vater et al., 2011).  
Dex is a synthetic glucocorticoid essential for osteoprogenitor cell differentiation (Vater 
et al., 2010) but also to enhance cell growth both alone and in combination with β-GP and asc 
(Coelho and Fernandes 2000). At an initial phase, this compound seems to induce AP activity 
and later, in the mineralising phase, increases the deposition of calcium (Coelho and Fernandes 
2000; Porter et al., 2003). However, glucocorticoids have been described to cause bone fragility 
and bone loss, via the inhibition of bone matrix proteins such as type I collagens and 
osteocalcin (Iu et al., 2005). These contradictory observations suggest that the dex effect on 
osteogenic differentiation is dependent on both the dosage and the timing of treatment (Porter 
et al., 2003; Iu et al., 2005, Park et al., 2010) and that dex is not required continuously, but only 
at particular stages, to generate the osteoblast phenotype (Beloti and Rosa 2005; Park 2010).  
  β-GP is enzymatically hydrolysed by alkaline phosphatase, serving as a crucial source 
of inorganic phosphate during matrix mineralisation (Chang et al., 2000) and it is almost entirely 
degraded during the first two weeks of culture (Coelho and Fernandes, 2000). When β-GP is 
added in combination with asc and dex causes an increase in AP activity (Park, 2010; Vater et 
al., 2010), but on its own leads to a decrease in the activity of this enzyme (Park, 2010). 
Additionally, β-GP seems to be the only of the three factors that by its own has the ability to 
form mineral deposits (Coelho and Fernandes, 2000).  
 Asc, or the more stable form, ascorbic acid 2-phosphate, has a mitogenic effect and is 
a cofactor for collagen hydroxylation (Vater et al., 2011), which is important for its synthesis and 
maturation (Takamizawa et al., 2004). In addition, asc appears to stimulate cell growth at any 
concentration (Takamizawa et al., 2004) with optimal maximum proliferation rate when at 
250µM (Choi KM et al., 2008).  
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The osteogenic factors dex, β-GP and asc are generally used in combination with FBS 
and, as previously discussed, the use of FBS presents several disadvantages when aiming for a 
clinical application. Therefore, there also is the need for replacing FBS by recombinant growth 
factors or human components during osteogenic differentiation. Several signalling pathways 
have been involved in osteoblast differentiation, including the Bone morphogenetic proteins 
(BMP), FGF, TGF-β, Notch and canonical Wnt pathways (Canalis, 2008; Engin and Lee, 2010; 
Komori, 2006; Rawadi et al., 2003; Valta et al., 2006; Yamaguchi et al., 1991; Zamurovic et al., 
2004). In a number of studies, activators and inhibitors of these pathways have been added to 
the culture medium as a mean to induce or repress differentiation, hence allowing a better 
understanding of the differentiation process and revealing candidate growth factors to replace 
FBS.  
In a different approach, Chevallier et al. (2010), have used platelet lysate, which 
contains a mixture of growth factors (including PDGF, FGF, IGF, TGF-β, PF-4 and PDEGF), 
and showed that it enhanced MSC expansion and replaced osteogenic agents during pre-
osteoblastic induction. In this study, MSC cultured in platelet lysate showed spontaneous 
osteoblastic gene expression and enhanced in vivo osteogenic capacity during ectopic bone 
formation (Chevallier et al., 2010). Moreover, cells expanded in other animal serum-free 
supplements, such as with AB hS, autologous hS and hPLP, seem to maintain their osteogenic 
potential (Kocaoemer et al.,2007; Doucet et al., 2005; Lange et al., 2007; Yamamoto et al., 
2003; Bernardo et al., 2006). Shahdadfar and colleagues observed that osteogenesis was 
sucessful in cells expanded with autologous hS, even though taking longer for this to be 
achieved (Shahdadfar et al., 2005).    
Pre-clinical and clinical studies have been performed for several bone disorders, 
including the genetic disorders Osteogenesis Imperfecta, infantile hypophosphatasia and 
osteopetrosis, as well as the acquired disease osteoporosis (Horwitz et al., 1999; Arthur et al., 
2009; Jethva et al., 2009). On the other hand,  in vivo studies on animal model transplantation 
showed that MSCs represent a good tool to improve bone regeneration (Jones and Yang, 2011) 
having, for example, increased bone formation in rat femur (Bruder et al., 1998) and 
osteoporotic rabbit (Wang et al., 2006) models. Also, a clinical trial involving the injection of 
autologous osteoblasts cultured from bone-marrow precursors showed a significant fracture 
healing improvement (Kim et al., 2009a).   
 MSCs also have the ability to differentiate into chondrocytes. For chondrogenesis to be 
achieved it requires close cell-to-cell contact and the addition of chemical supplements. The 
close cell-to-cell contact is generally achieved by promoting MSC concentration forming a three-
dimensional a micromass pellet. The cell pellet enhances the upregulation of extracellular cell 
matrix (ECM) interations, leading to the formation of pre-chondrocytes. After condensation, the 
cells become highly proliferative and change the ECM composition until reaching a mature 
chondroblast. Collagen type II is the most abundant fiber in this ECM, which is typical of 
articular cartilage. During this process, MSC fibroblastic shape changes to a large and round 
morphology. The three most important factors added to promote chondrogenesis are dex, asc 
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(which are commonly use in osteogenesis) and TGF- β, but BMPs, FGF and IGF are also 
commonly added. In animal serum free conditions, chondrogenic differentiation seems to be 
also maintained in the presence of autologous hS and hPLP, as it was for osteogenesis 
(Shahdadfar et al., 2005; Lange et al., 2007; Doucet et al., 2005). MSC differentiation into 
chondrocytes would allow their use in the treatment of several pathologies such as pain in the 
joints, which is mostly due to cartilage degeneration (Vater et al., 2010; Nesic et al., 2006) and 
avoid the need for orthopaedic surgery with all its complications and side effects (Koga et al., 
2009; Vater et al., 2010). 
 Finally, MSC are also able to differentiate into adipocytes. Adipocyte differentiation 
begins with the commitment of MSCs into pre-adipocytes that contain small lipid-rich vacuoles 
(Frith and Genever 2008; Can and Karahuseyionoglu et al., 2007). Subsequently, these cells 
develop into mature adipocytes, when, eventually, the lipid vacuoles fuse and fill the cells 
(Chamberlain et al., 2007). Along this process fibroblastic MSCs are converted to a spherical 
morphology (Vater et al., 2010.) To induce adipogenesis it is normally use dex, 3-isobutyl-1-
methyl-xanthine (IBMX), insulin and indomethacin are normally used. Some researchers 
additionally use triiodothyinine (T3), Asc-2-P and bFGF-2 (Vater et al., 2010). Upon induction 
the cells express specific adipocyte markers such as peroxisome proliferation-activated receptor 
γ2, lipoprotein lipase, and the fatty acid-binding protein aP2 (Pittenger et al., 1999; Chamberlain 
et al., 2007). Adipogenesis evaluation is performed histologically using the Oil Red dye, which 
marks the lipids in the vacuoles (Can and Karahuseyionoglu et al., 2007; Vater et al., 2010).       
The adipogenic differentiation potential of MSCs expanded in animal serum-free conditions is 
controversial as some authors argue that MSCs growing hPLP supplemented in culture media 
retain adipogenesis ability (Bernado et al., 2006; Doucet et al., 2005), whereas others show 
contradictory results (Lange et al., 2007).  As for the other mesenchymal lineages, adipocyte 
differentiation from MSCs would have important clinical applications following procedures or 
pathologies where large volumes of adipose tissue are lost (Gomillion and Burg 2006; Vater et 
al., 2010).  
 
1.5. Human Amniotic Membrane 
 
The promising use of MSCs in the field of regenerative medicine is undeniable, either 
through the local implantation of in vitro expanded autologous MSCs or of a pre-differentiated 
tissue matrix loaded onto suitable scaffolds.  
The ideal scaffold is expected to be biocompatible and should mimic the structure and 
biological function of native extracellular matrix. Active research is under way for the 
development of improved scaffolds, using a variety of natural and synthetic materials and 
advanced technologies (Sittinger et al., 2004; Tsigkou et al., 2009; Nöth et al., 2010). The 
human amniotic membrane (AM) is a good candidate for this application. The AM has as 
primary function the protection of the embryo during its development. Therapeutically, this 
membrane has been successfully used as a “biological dressing” over more than one hundred 
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years in cutaneous wounds and burns (Lo and Pope, 2009). However, it was only later that the 
great potential of the AM in ophthalmological, urological, gynaecological and neurological fields 
was realised (Tan et al., 2009; Burman et al., 2004; Sharifiaghdas et al., 2009; Ward et al., 
1989). The AM has recently been used in some studies as a substrate for MSC expansion and 
differentiation along different lineages with the aim of subsequent transplantation. Among other 
studies, Tan et al. (2011) have reported the successful chondrogenic differentiation of MSCs on 
AM for use as a cell delivery vehicle, Kim and colleagues showed that grafts of AM loaded with 
MSCs play an effective role during the healing of skin defects in rabbits (Kim et al., 2009b) and, 
in another report, a layer of somatic epidermal adult stem cells was cultivated and carried on 
AM into the ocular surface of a goat model of limbal stem cell deficiency (Yang et al., 2008).    
Importantly, a variant of the AM that is not rejected after allogeneic transplantation is 
currently prepared at the Tissue Bank of the Centro de Histocompatibilidade do Sul. During the 
preparation of this AM, apoptosis of the cells in the membrane is induced turning it 
immunologically inert, while preserving the tissue integrity. Also, the AM contains a variety of 
cytokines and growth factors (Koizumi et al., 2000) which may be responsible for its intrinsic 
regenerative and antiinflamatory properties (Fernandes et al., 2005; Insausti et al., 2010; Velez 
et al., 2010; Samandari et al., 2011). The high levels of growth factors such as EGF, bFGF, 
keratinocyte growth factor (KGF) and hepatocyte growth factor (HGF), support epithelialization 
and regulation of fibrosis and neovascularization process (López-Valladares et al., 2010). 
López-Valladares and colleagues have shown that there are growth factor variations depending 
on the age of AM donors and the gestational stage, as mothers under 35 years old with 38 to 39 
weeks of pregnancy have higher levels of growth factors (López-Valladares et al., 2010). 
Although it has not been proven, it is expected that higher levels of growth factors produce 
better clinical results (Koisumi et al., 2000; López-Valladares et al., 2010). The AM is thus a 
promising substrate for MSC attachment and differentiation and a safe and effective vehicle for 
transplantation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                             Introduction 
_____________________________________________________________________________
_ 
 25 
2. Materials and Methods 
 
2.1. Isolation of MSCs from different parts of UC 
 
In this study, MSCs were isolated from different parts of 26 human umbilical cords using 
a variety of methodologies. The UCs were obtained with written informed consent of the 
parturients from elective caesareans. Human umbilical cords were first washed in Hanks’ 
balanced salt solution (GIBCO; 14175-129) with antibiotics (Penicillin-Streptomycin and 
Gentamicin) and then processed for MSC isolation. This was accomplished using different 
combinations of mechanical and/or enzymatic and mechanical methods in search for an optimal 
one (see supplementary Table 1). MSCs were obtained from WJ (peripheral and total), vessels 
and whole cord. For the isolation of peripheral Wharton’ Jelly (pWJ) ), pieces of mesenchymal 
tissue were cut around the vessels from the outside part of the UC. MSCs from total Wharton’s 
Jelly (tWJ) were obtained by cutting open UC and subjecting the inner part to an initial 1h of 
enzymatic digestion for removal of the arteries and veins to isolate the WJ. The pWJ and tWJ 
mesenchymal tissue was then cut into small fragments and directly plated or submitted to a 4 to 
16h enzymatic digestion. The arteries and veins obtained by this method were also cut into 
small pieces and submitted to a 4h enzymatic digestion to isolate MSCs from vessels (V-UC). 
To obtain the MSCs from whole parts of umbilical cord (W-UC) a cord piece with 2-3cm was cut 
into small fragments and submitted to a 4h enzymatic digestion. The enzymatic solution used 
for tissue digestions was composed of 0.1-2 mg/ml collagenase XI (Sigma; C9697) alone or 
with 100U/ml hyaluronidase (Sigma; H2126). In some cases, a subsequent digestion with 
Tryple Express® (a trypsin replacement from Invitrogen; 12604-013) was performed. The 
dissociated cells were then washed in Dulbecco’s phosphate buffered saline (DPBS - GIBCO; 
14190-169), resuspended in MSC/FBS medium or in StemPro® MSC SFM medium (GIBCO; 
A10332-01) and cultured on tissue culture plastic plates at 37ºC in a 5% CO2 humidified 
incubator. 
 
2.2. MSC in vitro culture 
 
For routine in vitro MSC expansion, cells were cultured in MSC-FBS medium on tissue 
culture plastic flasks (Greiner; C6481-200EA) at 37ºC in a 5% CO2 humidified incubator. 
MSC/FBS medium was composed of DMEM-F12 (1:1) (GIBCO; 21331-020), 2mM L-Glutamine 
(GIBCO; 25030-024), 15mM HEPES (GIBCO;15630-056), 100U/ml penicillin (GIBCO; 15140-
122), 100μg/ml streptomycin (GIBCO; 15140-122), 5 μg/ml Gentamicin (GIBCO; 15710-049) 
and 10% MSC-qualified Fetal Bovine Serum (FBS – GIBCO; 12662-029). Every 2-3 days, 
approximately half of the medium was replaced by fresh medium and when reaching 
approximately 80% confluence the cells were passaged by dissociation using Tryple. The cells 
were then counted using a Neubauer hemocytometer and replated at 0.5 or 1x10
4
cells/cm
2
. For 
low confluence experiences cells were replated at 200cells/cm
2
 in 75-cm
2
 flasks (Greiner; 
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C7106-120EA) MSC-FBS medium. Low passage MSCs were also frozen for later use in 
DMEM-F12 containing 10% tissue-culture grade dimethyl sulfoxide (DMSO, Merck; K28452252-
101) and 10% FBS, kept at -80ºC for a few days and then stored in liquid nitrogen. 
 
2.3. Colony forming units (CFUs) assay 
 
For CFUs analysis, cells were plated at 200cells/cm
2
 and cultured in petri dish (Nunc; 
150350) in MSC-FBS medium. The medium was replaced twice a week and cultures were 
stopped at day 14. Colonies were washed with PBS, fixed with 0.05% glutaraldehyde (Sigma; 
G6257-10X10ML) for 5min and stained with 0.5% aqueous crystal violet (Sigma; C0775-25G). 
The colonies were then washed 3 times with PBS and the colonies were counted. All 
experiments were performed in triplicates.    
 
2.4. Immunofluorescence 
2.4.1. Flow Cytometry 
 
For the immunophenotypic characterization of UC MSCs, the cells were analysed for 
the presence of the surface markers CD90, CD73, CD105, CD44, CD34, CD45, CD19, CD14 
and HLA-DR using the specific fluorochrome-conjugated monoclonal antibodies listed on table 
2. Briefly, the cells were dissociated into a single cell suspension and approximately 1x10
5
 cells 
were incubated with the appropriate monoclonal antibodies (see table 2) in 0.5%BSA/PBS 
(Sigma;A7284-50ML) for 1 hour in the dark. Following this incubation, the cells were washed in 
2mL of PBS and centrifuged. The pellet was then resuspended in PBS and analysed by flow 
cytometry in a FACSCalibur instrument with CellQuest software (both BD Biosciences). 
 
Table 2: List of monoclonal antibodies used for MSC immunophenotyping. 
Antigen Antibody Clone Isotype Fluorescence Brand 
CD34 8G12 Mouse IgG1, κ PerCP-Cy5.5 BD Biosc. 
CD34 8G12 Mouse IgG1, κ PE BD Biosc. 
CD19 HD37 Mouse IgG1, κ PE BD Biosc. 
CD14 MφP9 Mouse IgG1, κ PE BD Biosc. 
HLA-DR L243 Mouse IgG1, κ PerCP BD Biosc. 
CD44 IM7 Rat IgG2b, κ FITC BioLegend 
CD44 IM7 Rat IgG2b, κ PE-Cy7 BioLegend 
CD45 HI30 Mouse IgG1, κ PerCP BioLegend 
CD73 AD2 Mouse IgG1, κ PE BioLegend 
CD90 5E10 Mouse IgG1, κ APC BioLegend 
CD105 43A3 Mouse IgG1, κ FITC BioLegend 
CD105 43A3 Mouse IgG1, κ APC BioLegend 
bAP 0.G.2 Mouse IgG1, κ FITC Abcam 
TNAP B4-78 Mouse IgG1, κ FITC 
Santa Cruz 
Biotechnology, inc 
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Osteocalcin 190125 Mouse IgG1, κ PE R&D System 
 
2.4.2. Fluorescence Activated Cell Sorting (FACS) 
 
The population enrichment in for CD105
low
 and CD105
high
 or CD105
 low
 /CD90
low
 and 
CD105
high
/CD90
high
 MSCs was performed by FACS sorting. The cells expanded in MSC/FBS 
medium were dissociated using Tryple and the cell suspension were passed through a 50µm 
cell strainer (Partec; 04-004-2327) to obtain a single cell suspension and approximately 1x10
6
 
cells were incubated with CD105 and CD90 monoclonal antibody (see Table 2) in 
PBS/0.5%BSA for 1 hour in the dark in a sterile environment. Following this incubation, the cells 
were washed in 2mL of PBS and centrifuged at 1400rpm. The resuspended pellet in PBS was 
passed through FACSAria instrument (with FACS Diva software) (both BD Biosciences) for 
sorting of the populatons of interest. Then, CD105
low
(/CD90)
low
 and CD105
high
(/CD90)
high
 MSC 
populations were gated and sorted directly to fresh culture medium containing antibiotics. The 
sorted populations were then plated into tissue culture plates with 1mL of MSC/FBS medium.   
 
2.5. Gene Expression Analysis 
 
The gene expression of markers of MSCs and of different stages of osteoblastic 
differentiation was analysed by RT-PCR. With this purpose, cells were dissociated, pelleted and 
immediately stored at -80ºC until RNA extraction. RNA was extracted using the TRIzol reagent 
(Invitrogen; 15596-026) or the RNeasy mini kit (Qiagen; 74104) in combination with the in 
column DNase digestion set (Qiagen; 79254), and quantified using a Beckman Coulter DU 530 
UV/Vis spectrophotometer or NanoDrop
®
 2000 spectrophotometer. The extracted RNA was run 
on a 1.8% agarose gel to verify its quality and integrity. The RNA was then reverse transcribed 
using the SuperScript III Reverse Transcriptase system (Invitrogen; 18080-129). 1μg of total 
RNA, 1 μl of 50 μM random primers (Applied Biosystems) and RNase free water (Sigma; 
95284-100ML) were mixed to a final volume of 10 μl. After a 5 minute incubation at 65°C the 
samples were put on ice and a mix containing 0.5mM Deoxynucleotide set (Sigma; DNTP100-
1K), 5 mM DTT, 2 U/μl RNaseOUT RNase inhibitor (Invitrogen; 10777-019) and 10 U/μl 
Superscript III in first strand buffer was added. A reaction mixture without the enzyme was also 
set up as a negative control (designated “-RT”). The mixture was incubated at 25°C for 5 min, 
50°C for 1h and at 70°C for 15 min. The cDNAs were diluted 1:10 in dH2O and kept at -20°C 
until PCR analysis. 
For RT-PCR amplification a reaction mix was set up as follows: 100 ng of cDNA were 
added to 10 μmol of each primer (Eurofins MWG Operon), 0.2 mM dNTPs, 1 unit of AmpliTaq 
DNA Polymerase and PCR Buffer (Applied Biosystems; N8080166), in a total volume of 30 μl. 
Negative controls included the –RT samples and the non-template control (containing dH2O 
instead of cDNA). PCR was performed on a GeneAmp PCR System 2720 (Applied Biosystems) 
and PCR conditions included an initial denaturation step at 94ºC for 5 minutes, followed by 35 
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amplification cycles of 45 seconds at 94ºC, 30 seconds annealing at 59ºC and 45 seconds 
extension at 72ºC, followed by a final elongation step of 10 minutes at 72ºC. The resulting PCR 
products were size-fractionated by electrophoresis in a 1.8 % agarose gel containing ethidium 
bromide, and visualised under ultraviolet light in a Biorad Gel Doc XR transiluminator. Specific 
primers for the amplification of genes of interest were designed using the NCBI primer design 
tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/), and are listed on table 3. 
 
Table 3: Primers used for the gene expression analysis of markers of MSCs and of osteoblastic 
differentiation. 
Gene symbol Forward primer (5’→3’) Reverse primer (5’→ 3’) 
Amplicon size 
(bp) 
ACTB CCGCCAGCTCACCATGGATGA TCTTGCTCTGGGCCTCGTCG 197 
CD90 (Thy1) TCGCTCTCCTGCTAACAGTCT CTCGTACTGGATGGGTGAACT 134 
CD73 (NT5E) AGTGAGGGGTGTGGACGTCGT TGCCAAAAGCATAGGCCTGGACT 158 
CD105 (ENG) ATCCTCCTCCGACTGGGCCAA TGCGCAGCTCAGTTCCACCTT 228 
RUNX2 TCCTATGACCAGTCTTACCCCT GGCTCTTCTTACTGAGAGTGGAA 190 
 
 
2.6. Xeno-free culture of UC-MSCs 
 
Following MSCs isolation, their culture in a chemically defined medium was tested. 
As a first approach, the commercial serum-free StemPro® MSC SFM medium was used. This 
medium is supplemented with human platelet-derived growth factor-BB (PDGFBB), basic 
fibroblast growth factor (bFGF) and TGF-b1, a combination of growth factors that has been 
shown to be able to promote extensive propagation with retained phenotype, colony-forming 
unit, and differentiation potential (Ng et al., 2008; Chase et al.,2010). 
Subsquentely, human AB serum, platelet-lysate and plasma were test as suitable 
alternatives for FBS replacement for MSC expansion. Platelet-lysate was obtained by platelet 
apheresis procedures performed at Instituto Português do Sangue (IPS, Lisbon, Portugal). One 
pool of platelets was centrifuged twice for 30min at 3850rpm and the platelet pellet was 
resuspended in DMEM-F12. The plasma supernatant was collected, filtrated in a Stericup 
(Millipore; SCGPUO1RE), aliquoted and frozen at -80°C (hP). Platelet in medium samples and 
the remaining platelets in plasmas were frozen at -80°C and subsequently thawed at 37°C to 
obtain platelet-released growth factors. Platelet bodies were then eliminated by centrifugation of 
30min at 3850rpm (twice) and it was obtained supernatant of the platelet-lysate in plasma 
(hPLP) and the platelet-lysate in medium (hPL). After filtration, hPLP and hPL were aliquoted 
and frozen at -80°C. For this study a commercial human AB pooled serum (Lonza; 14-498E) 
was also used in this study.  
For the studies of xeno-free media, tissue culture plates were pre-coated with human 
plasma fibronectin (2μg/cm
2
 – Millipore; FC010-1mg) for 30 min. Subsequently, early passage 
MSCs were dissociated with Tryple, and 1 x 10
4
 cells were plated per cm
2
 in the different xeno-
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free media. To the media supplemented with hPLP and hP was added heparin at a 
concentration of 1U/mL (Biochron AG, L6510) to avoid media coagulation. To all platelet lysate, 
plasma and serum conditions were added 250µM asc (Sigma; A8960-5G) to enhance cell 
proliferation.  
 
2.7. Multilineage differentiation and detection methods 
 
UC-MSCs were induced to adipogenesis, osteogenesis and chondrogenesis and 
detected by histological staining, RT-PCR and immunophenotypiing.  
Osteogenic differentiation of MSCs was induced following protocols relatively well 
established (Vater et al., 2011). Briefly, a monolayer of MSCs is cultured in the presence of 
dexamethasone (dex), beta-glycerophosphate (b-GP) and ascorbic acid (asc), leading to the 
formation of a mineralised matrix in 4 to 6 weeks. In this study, small variations within this 
osteogenic induction protocol were tested in search for the most efficient one. MSCs were thus 
plated on tissue-culture plastic, with or without fibronectin precoating. Cell confluences ranged 
from 0.5 to 2 x 10
4
 cells/cm
2
, and several differentiation media conditions were tested: the 
MesenCult osteogenic stimulatory kit (Stem Cell Technologies; 5404), StemPro® Osteogenesis 
differentiation Kit (GIBCO; A1007201) and DMEM-F12 (1:1), DMEM-KO (GIBCO; 10829-018), 
DMEM-LG (GIBCO; 11054-001) and MesenCult basal medium supplemented with 10% FBS, 
100 nM dexamethasone (Sigma; D4902-25MG), 0.2 mM L-ascorbate (Sigma; A8960), and 10 
mM b-glycerophosphate (Sigma;G9422-10G). 
After 14 to 21 days, during which the medium was changed every 3 days, osteoblastic 
differentiation was assessed by flow cytometry immunophenotyping, gene expression analysis, 
alkaline phosphatase activity assays and by Alizarin Red S (Sigma; A5533-25G) or von Kossa 
staining for detection of calcium deposition. This characterisation of the differentiating cells in 
terms of expression of surface markers, gene transcription and specific functions of each of the 
differentiation phases (osteoblast proliferation, matrix deposition and mineralization phase) 
allows following the differentiation process. 
Alkaline Phosphatase activity of osteoblastic differentiation was assessed using the 
Alkaline Phosphatase kit from Sigma (Sigma; 86R-1kt). Briefly, cells were fixed in Citrate-
acetone-formaldehyde fixative solution for 30 seconds, rinsed in deionised water for 45 seconds 
and subsequently incubated with alkaline-dye mixture at room temperature for 30 minutes 
(protected from the light), rinsed for 2 minutes in deionised water and left to dry before analysis. 
Mineralised deposits were visualised by von Kossa or Alizarin Red S staining after 21 to 
40 days. For von Kossa staining, cells were fixed in 4% PFA for 20 min and exposed to 1% 
silver nitrate under bright light for 60-90min (this leads to deposition of silver, which can then be 
visualised as metallic silver, by replacing the calcium reduced by the strong light). Following 
rinsing in distilled water, unreacted silver was removed with 5% sodium thiosulfate for 5 
minutes, rinsed again in distilled water, and finally visualised the brownish mineralized deposits. 
For Alizarin Red staining, cells were fixed with PBS/10% Formaldehyde (Sigma; 3220-500ML) 
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for 15 min, washed 3 times with ddH2O and staining with 0.1% Alizarin Red/ddH2O working 
solution (adjusted the pH to 4.1-4.3) for 1 hour with a slow circular agitation. The cells were then 
rinsed 3 times with PBS for 5-10min with agitation and visualized the reddish mineralized 
deposits.    
Adipogenic differentiation of MSCs was induced with commercial StemPro® 
adipogenesis differentiation kit (GIBCO; A1007001). MSCs were plated at cells density of 
1x10
4
cells/cm
2 
and culture medium was replaced every 3 days. After 14 days in culture cells 
were washed in PBS and fixed with 0.5% glutaraldehyde (Sigma) for 5min. After washing, the 
cells were stained with 0.5% Oil Red O solution in 60% isopropanol (Sigma; O0626-25G) 
working solution, washed and visualised. 
Chondrogenic differentiation of MSCs was induced with commercial StemPro® 
chondrogenic differentiation kit (GIBCO; A1007101). MSCs were plated at cells density of 
1x10
4
cells/cm
2 
in a fibronectin pre-coated tissue culture plates and culture medium was 
replaced every 3 days. After 21 days in culture cells were washed in PBS and fixed with 0.5% 
glutaraldehyde for 5min. After washing, the cells were stained with 0.5%Toluidine O blue 
(Sigma; 198161-5G) working solution, washed and visualised. 
 
2.8. Osteogenic differentiation of MSCs on hAM 
 
MSCs were plated on AM processed by the tissue bank of the Centro de 
Histocompatibilidade do Sul to test this substrate as a support material for MSC osteogenic 
differentiation. Two types of processed AM were tested: dehydrated AM on a silicone base, and 
AM frozen at - 80ºC in 10% DMSO. In both cases the AM was left to hydrate or equilibrate in 
culture medium for approximately 24h. Due to problems securing the AM straight in the tissue 
culture plate during these experiments, either the plates were pre-coated with fibronectin or a 
teflon ring was placed on top of the AM to prevent its deformation. MSCs were then plated on 
the AM, and induced to differentiate in the appropriated media. Osteoblast differentiation, and in 
particular the formation of an osseous matrix on the AM was assessed by detection of alkaline 
phosphatase activity and calcium deposition as previously described. To confirm that AMs were 
completely decellulerized neutral red staining was performed in AMs with and without MSCs 
and in MSCs plated in tissue plastic. The neutral red stock solution (4%) was diluted 1:100 in 
MSC culture medium. The working solution was prepared the day before use and was let at 
37ºC overnight. In the next day, the medium was replaced by oil red working solution for 4 
hours. After oil red removal, the cells were visualized in PBS to a better reddish staining 
observation.  
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3.9. Data Analysis 
 3.9.1. Statistical Analysis 
 
Statistical analysis was performed using Excel software (Microsoft Office Excel 2007, 
Microsoft Corporation). Data are presented as the mean ± standard deviation. When 
appropriate, statistical comparisons were performed using student’s t-test. Differences were 
considered statistically significant when p<0.05.  
 
3.9.2 Image Acquisition 
 
Images were obtained in Olympus CKX41 microscope with Canon IXUS8015 camera 
and Olympus IX71 with Olympus DP70 camera. 
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3. Results 
 
3.1. MSC can be successfully isolated from different parts of UC 
 
In this study we have initially attempted to isolate MSCs from different parts of human 
UC in order to determine the most suitable stem cell source within this tissue. For the isolation 
of MSCs from the different parts of the UC, various methods were tested, both exclusively 
mechanical and combinations of mechanical and enzymatic procedures (see supplemental 
Table 1). Of the 26 human UC processed, MSCs from WJ (peripheral and total), vessels and 
whole cord were obtained. MSCs from peripheral WJ tissue (pWJ-UC) were isolated by cutting 
the mesenchymal tissue from the exterior part of the UC around the vessels  into small 
fragments and directly plating or submitted them to a 4 to 16h enzymatic digestion (with 
collagenase, and/or hyaluronidase). For the isolation of MSCs from total WJ (tWJ-UC) and 
vessels (V-UC) the umbilical cord was cut open lengthwise and subjected to an initial 1h 
enzymatic digestion. The vessels were then separated from the remaining WJ and each of 
these components was separately digested for 4 to 16h for MSC isolation (see Supplementary 
Figure 1). To obtain MSCs from whole umbilical cord (W-UC), a segment of the cord (including 
both vessels and WJ tissue) was cut into small pieces and submitted to a 4 to 16h enzymatic 
digestion. Some samples were subsequently subjected to a further 20min digestion with the 
trypsin replacement Tryple. 
The exclusively mechanical method was not very efficient as only a minority of single 
cells was obtained and the bigger pieces did not effectively adhere to the tissue culture flask. 
The collagenase digestion significantly increased the tissue dissociation, and thus the number 
of single cells obtained, while it did not meaningfully compromise cell viability. The best cell 
dissociation/viability ratio was obtained using a collagenase concentration around 0.5mg/ml. 
Adding hyaluronidase (at a concentration of 100 U/ml) to the digestion increased tissue 
dissociation and considerably reduced the viscosity of the solution, facilitating the pelleting and 
washing steps. In addition, the use of hyaluronidase allowed a reduction in the duration of the 
enzymatic treatment, a crucial factor as it had to be enough to allow tissue dissociation but it 
also had a decisive effect on cell viability. We observed that 4 hours of enzymatic treatment 
after cutting the tissue into small fragments was a reasonable time for tissue digestion. Tryple 
digestion did not significantly improve cell dissociation and therefore this step was eliminated. 
For some of the samples the digested tissue was finally filtered with a cell strainer, a step that 
removed undigested cell clumps producing a “cleaner” cell suspension. However, it is not clear 
whether this improved cell recovery. 
Even though different efficiencies were observed between methods and tissue sources, 
MSC cultures were successfully established from all the 26 UCs (Table 4). From these cords, 
13 pWJ-UC, 14 tWJ-UC, 15 W-UC and 12 V-UC were obtained. Of these, the cells of two pWJ-
UC and one tWJ-UC got bacterial contamination at the time of the first passage, whereas the 
remaining MSCs were efficiently propagated in culture for up to over 12 passages in MSC-FBS 
medium (DMEM:F12 with 2mM L-Glutamine, 15mM Hepes, 10% MSC-qualified FBS and 
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Table 4. Summary of the characterisation of mother’s age, gestational stage, elapse time between harvest 
and processing the cord (Proces. Time) and MSCs tissue source in each cord. (UC- umbilical cord; pWJ- 
peripheral Wharton’s jelly; tWJ- total Wharton’s jelly; W- whole umbilical cord; V- vessels)  
 
antibiotics (100 U penicillin and 100 µg streptomycin / ml, 5µg/ml Gentamicin and amphotericin 
B) for  the first two passages. The 51 MSC cell lines showed good cell viability at every step of 
expansion, freezing and thawing.  
Some clinical parameters were collected from donors such as mother’s age that range 
from 25 to 40 years old and gestational stage at the time of birth, which range from 37-41 (Table 
4).  The elapse time between harvest and processing the cord was also analysed and this was 
not beyond 2 days (Table 4).  
The morphology, growth behaviour, immunophenotype, gene expression profile and 
differentiation abilities of the in vitro expanded cells were subsequently investigated. 
 
 
 
UC nº Mother’s Age Gestational Stage (Weeks) Proces. Time Tissue source 
1 27 39 1 day pWJ 
2 32 40 same day pWJ 
3 40 39 1 day pWJ 
4 34 37 1 day pWJ 
5 37 39 1 day tWJ 
6 38 38 1 day pWJ 
7 35 38 1 day pWJ 
8 28 39 1 day tWJ 
9 32 39 1 day pWJ 
10 33 39 1 day pWJ/tWJ 
11 34 38 1 day tWJ 
12 37 38 1 day pWJ /W/V 
13 33 38 1 day pWJ /W/V 
14 39 39 1 day pWJ /W/V 
15 35 40 1 day pWJ /W/V 
16 34 39 2 days tWJ/W/V 
17 36 40 1 day tWJ/W/V 
18 39 38 1 day pWJ/W 
19 25 39 1 day tWJ/W/V 
20 31 39 2 days tWJ/W/V 
21 36 38 2 days tWJ/W/V 
22 27 39 Same day tWJ/W/V 
23 31 41 1 day tWJ/W/V 
24 32 38 1 day tWJ/W/V 
25 35 39 1 day tWJ/W 
26 32 41 1 day tWJ/W 
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3.2. Differences in the number of MSCs isolated from WJ-UC and W-UC, but 
similar MSCs morphology and immunophenotype 
 
Primary cultures obtained from WJ-UC and W-UC initially showed a variable 
morphology mostly with flattened striated cells but also a significant proportion of fibroblastoid 
shaped cells (Figure 4A). In some cases, clusters of cells with a typical endothelial morphology 
were also observed, but these were progressively lost during culture. After few days in culture, 
MSCs from both tissues grew in colonies and were dissociated and replated 10 to 15 days after 
plating. MSC from W-UC generally reached confluence and needed passaging after 
approximately 14 days in culture, a shorter time then cells from other tissue sources. Also, as 
shown in Figure 4B, at the time of the first passage, more cells per gram of tissue were  
systematically obtained from W-UC tissue compared to WJ-UC (n=4; Figure 4B). After 
passaging, the cell culture became more homogeneous, containing predominantly spindle-
shaped fibroblast-like cells, with no significant differences depending on the tissue source or the 
isolation method.  
In order to characterise the cells isolated from the tWJ-UC and W-UC, the cell surface 
antigens present on these cells were analysed by flow cytometry (FC) immediately after tissue 
dissociation. This analysis showed that the majority of the cells from both tissue sources 
express very low levels of the MSC-characteristic markers CD73 (1,88±1,27 for tWJ and 
4,98±0,78 for W-UC), CD105 (2,16±1,39 for tWJ and 6,68±1,84 for W-UC), CD44 (5,23±1,66 for 
tWJ and 9,56±0,92 for W-UC) and CD90 (13,02±7,41 for tWJ and 30,71±7,64 for W-UC) (Figure 
4C). At this stage, a small proportion of cells also expressed hematopoietic markers such as 
CD34 (1,12±0,77 for tWJ and 3,76±0,38 for W-UC) and CD45 (4,67±2,09 for tWJ and 
10,62±2,06 for W-UC) (Figure 4C), although the percentage of CD34 and CD45 expressing 
cells  was 2 to 3 times higher in W-UC than in WJ-UC (n=4).  
After the first passage, the number of positive cells for the MSC-characteristic markers 
increased significantly to approximately 80% for CD44 and more than 90% for the other 
markers, in cells from both tissue sources (Figure 4C). Regarding the negative markers, the 
expression of CD34 and CD45 remained low for WJ-UC MSCs and decreased to similarly low 
levels in W-UC (Figure 4C) 
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Figure 4. Characterisation of primary cultures of UC-derived MSCs A) Representative phase contrast 
images of cells isolated from tWJ-UC and W-UC after 15 days of culture in standard MSC-FBS medium. 
Primary cultures of W-UC (b) were generally more confluent than WJ-UC (a) and both included cells with a 
variable morphology with flattened as well as fibroblastic-like cells. Image magnification: 400x. B) 
Graphical representation of the number of cells obtained from each different tissue source after 15 days in 
                                                                                                                                   Results 
_____________________________________________________________________________
_ 
 36 
culture, normalised to the tissue weight. Identical shaped symbols represent results from the same UC 
donor. For each donor, more cells were consistently obtained from W-UC (green symbols) than from WJ-
UC (orange symbols) C) Flow cytometry immunophenotyping of tWJ-UC and W-UC cells on the day of 
isolation (Day1) and after the first passage (Passage1). Histograms demonstrating the expression of the 
surface antigens (red line) were plotted against isotype controls (black lines) for unspecific fluorescence. 
The percentage of positive cells and MFI are given on top of each histogram. During primary culture there 
is a substantial increase in the expression of CD73, CD105, CD44 and CD90 antigens whereas CD34 and 
CD45 remained low or further decreased in W-UC. Shown is one representative out of 5 independent 
experiments.      
 
 
3.3. MSCs proliferation change from the early to the late passages for different 
tissue source 
 
During cell passaging, the cell morphology remained relatively homogeneous, 
predominantly with spindle-shaped fibroblast-like cells, until late passages (passage 12 to 16) 
(Figure 5A c). After passage 16, MSCs changed to a more stretched and branched morphology 
(Figure 5A d) for both WJ-UC and W-UC.  
In Colony-forming unit (CFU) assay, it was observed great heterogeneity in morphology, 
size and number of colonies with apparent no correlation with tissue source (Figure 5B a-d). 
To assess the growth behaviour of the established cell lines, term growth curves were 
generated. Cells at an early passage (P4) were thus counted every 24 hours along 4 days. As 
shown in Figure 5C MSC lines obtained from different tissue sources showed a similar growth 
profile. The long term growth response of the different cell lines was subsequently studied. For 
this, the total number of cells at each passage, along 9 passages, was calculated as a ratio of 
total number of cells harvested to total number of cells seeded, multiplied by the total number of 
cells from the previous passage (Nekanti et al., 2010). Cultured MSCs from the different tissue 
sources analysed showed similar cell proliferation profiles at low passages (P3 to 8) (Figure 
5D).  During the initial passages, pWJ-UC exhibited a slightly slower growth when compared to 
W-UC, even though following a similar growth pattern (Figure 5C and D). . However, from 
passage 8, the cell proliferation pattern differed depending on the tissue source. While pWJ-UC 
cells maintained the same tendency of slow proliferation, as for lower passages (Figure 5D), W-
UC MSCs further increased their growth rate until passage 10, when a peak was reached 
(Figure 5D). Finally, tWJ-UC MSCs grew faster in higher than in lower passages and continued 
to increase beyond passage 12, outpacing the W-UC MSCs growth (Figure 5D).  
The immunophenotypic analysis of MSCs isolated from tWJ and W-UC showed that the 
percentage of positive cells for CD73, CD105, CD44 and CD90 initially increased drastically. 
Along continuous passaging, MSCs from both tissues remained highly positive for CD73, 
CD105, CD44 and CD90 (over <90% positive cells) and negative for CD19, CD14, CD45, CD34 
and HLA-DR (see Figure 6 and Supplementary Figure 2). In higher passages the mean 
fluorescence intensity (MFI) for CD73 and CD105 became quite variable independently of tissue 
source. However, in higher passages, the CD44 MFI increased in almost all the MSCs 
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Figure 5. Morphological and proliferative features of UC-MSCs along time in culture. A) 
Representative phase contrast images of MSC at the time of the first passage (a), and after 3 (b) 12 (c) or 
19 (d) passages in standard MSC-FBS medium. Both WJ and W-UC cells initially show a variable 
morphology with flattened and fibroblastic-like (a) whereas after passaging the cultures become more 
homogeneous, mainly with spindle shaped or fibroblastoid cells (b-d). Images magnification: 400x. B) 
Representative images of crystal violet stained colony forming units (CFUs) showing the heterogeneous 
size, morphology and number of colonies of different MSC lines. C) Growth curves of MSCs isolated from 
different UC tissue sources grown in standard MSC-FBS medium for 4 days (96 hours). Data are 
expressed as mean ± standard deviation. D) Long term growth curves representing the cumulative cell 
expansion rates of pWJ (blue line), tWJ (orange line) and W-UC MSCs (green line) cultured in standard 
MSC-FBS medium. Total number of cells at each passage was calculated as the ratio of the total number 
of harvested cells to the total number of cells plated, multiplied by the total number of cells from the 
previous passage. The results represent the cumulative expansion rates (mean ± standard deviation) of 
the three different tissue source MSCs plated at a density of 1 x 10
4
cells /cm
2
 and grown for 12 passages.  
 
 
analysed (n=6/7) and for CD90 this value diminished (n=6/7). According to some authors, 
SSEA-4 and alkaline phosphatase antigens would be expressed in MSCs, which would indicate 
an evolutionary proximity between these cells and embryonic stem cells (Fong et al., 2007). Our 
results also revealed some positive cells for SSEA-4 (≈1-10%) but alkaline phosphatase antigen 
was not detected in MSCs (data not shown).    
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Figure 6. Expression profiles of MSC markers in cells expanded in standard MSC-FBS medium. 
Flow cytometry analysis of the expression pattern of MSC cell surface markers in primary cultures (P1), 
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and cells at low passages (P3-P6) and high passages (P12-P16). An increase in CD44, CD73, CD90 and 
CD105 constant low levels of CD34, CD45, HLA-DR, CD14 and CD19 were observed during the several 
passages. Representative histograms demonstrating the expression of the surface antigens (red line) were 
plotted against isotype controls (black lines) for unspecific fluorescence. The percentage of positive cells 
and MFIs are given on top of each histogram. The last column shows the percentage of positive cells for 
each marker through several passages. Dots and bars represent the mean ± standard deviation of the 
results for three different MSCs stem cell lines.  
 
 
 
3.4. StemPro MSC SFM induced a decrease in CD105 antigen  
 
An adequate clinically compatible culture medium should support MSC expansion while 
maintaining the essential properties, phenotype, and multilineage potential of these cells.   
Therefore, the expansion potential of the isolated MSCs was tested in the commercial 
serum-free StemPro® MSC serum free medium (Invitrogen), which is supplemented with 
human platelet-derived growth factor-BB (PDGF-BB), basic fibroblast growth factor (bFGF) and 
TGF-β1 (Chase et al., 2010).  
Initially, established MSC cell lines were expanded in the StemPro serum free medium 
(SP-MSC SFM) and the cell growth and phenotype compared to MSC expansion in FBS-
containing medium.  An immediate limitation observed in the use of the StemPro medium is in 
terms of cell adhesion since in this condition the cells are not able to efficiently adhere to the 
tissue culture plastic vessels, requiring pre-coating with an adequate substrate such as human 
fibronectin.  
Therefore, for this experiment the cells were plated on fibronectin-coated plates at the 
cell density of 1x10
4
cells/cm
2
 in the two types of medium.  Every 3 days, when confluence was 
reached, the cells were dissociated and replated. This experiment was extended for eight 
passages (28 days) and MSC specific markers analysed before experience plating and after 
one, four and eight passages in each type of medium. MSCs were seeded and reached 
confluence 4 days after plating.  
Morphologically, cells growing in SP-MSC SFM exhibited a narrower and more 
elongated shape than in FBS medium, although after harvesting MSCs in SP-MSC SFM 
observed in hemocytometer were smaller than those in FBS-containing medium (not 
shown).The analysis of the growth curves for the two culture conditions (Figure 7A) showed that 
MSC growth in SP-MSC SFM followed a similar pattern to that of MSCs in FBS containing 
medium for up to 8 passages.  
The phenotype of cells both in serum-free and serum-containing medium was assessed 
at the first, fourth and eight passages in terms of cell surface expression of the MSC specific 
markers (Figure 7B). The percentage of positive cells for the cell surface proteins CD73, CD44 
and CD90 was comparable for the two growth conditions whereas CD105  was consistently 
expressed in a lower percentage MSCs growing in SP-SFM, a difference that increased with 
time in culture (p<0.05) (Figure 7B).                
As a further test to the competency of the StemPro MSC SFM, MSC cultures were 
attempted to be established directly in this medium. This was accomplished with a very low  
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Figure 7. Characterisation of MSCs cultured in StemPro serum-free medium in comparison to 
MSC/FBS medium. A) Growth curves representing the cumulative cell expansion rates of MSCs cultured 
in either serum free (SP-MSC SFM) or FBS-containing (MSC-FBS) medium. Total number of cells at each 
passage was calculated as the ratio of the total number of harvested cells to the total number of cells 
plated, multiplied by the total number of cells from the previous passage. MSC show a similar growth 
pattern in both types of medium for up to 8 passages. The results represent the cumulative expansion 
rates (mean ± standard deviation) of 3 different MSC cell lines plated at a density of 1 x 10
4
cells /cm
2
. B) 
Flow cytometry immunophenotyping of MSCs expanded on SP-MSC SFM and MSC-FBS medium at 
passage 4 (P4) and passage 8 (P8). During several passages the high levels of expression of CD73, 
CD44 and CD90 antigens are maintained in both types of media whereas CD105 marker expression 
decreases in MSCs expanded in SP-MSC SFM. Histograms demonstrating the expression of the surface 
antigens (red line) were plotted against isotype controls (black lines) for unspecific fluorescence. The 
percentage of positive cells and MFI are given on top of each histogram. Shown is one representative out 
of 3 independent experiments. The last column shows a graphical representation of the average 
percentage of CD73, CD90, CD44 and CD105-positive MSCs when cultured in MSC-FBS or in SP-MSC 
SFM medium for 0, 1, 4 and 8 passages. Dots and bars represent the mean ± standard deviation of the 
results for three different MSC stem cell lines. A high percentage of CD73, CD44 and CD90-positive cells 
is maintained in SF medium, but the number of CD105 expressing cells decreases in this culture condition 
compared to the FBS-containing medium (**p<0.01).  
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efficiency as only 1 in 3 W-UC MSC and 0 in 3 WJ-UC cell lines were successfully established 
from the primary cultures (data not shown).  
The differences observed in morphology, expression of surface antigens and derivation 
efficiency between MSCs cultured in FBS containing medium and in StemPro-MSC-SFM 
indicated that this commercial medium is not a very suitable substitute for FBS.  
 
 
3.5. hABS is a good xeno-free alternative culture supplement for FBS replacement 
 
In this study, human platelet-lysate in plasma (hPLP), human platelet-lysate in DMEM-
F12 (hPL), pooled human plasma (hP) and pooled human AB serum (hABS) were tested as 
FBS substitutes with the aim of obtaining a xeno-free MSC culture condition. Initially, we tested 
two different concentrations of these supplements and observed that better cell viability was 
obtained using a concentration of 5% for hPLP, hPL and hP and 10% for hABS. Although MSCs 
cultured in media containing any of these human component supplements did not require pre-
coating with a specific substrate, the use of fibronectin enhanced MSC performance in culture 
media containing hPLP, hPL and hP (not shown). Also, as previously published results reported 
(Choi KM et al., 2008; Potdar and d’Sousa, 2010), the addition of ascorbic acid (asc) at a 
concentration of 250 µM improved MSC growth (see Supplementary Figure 3) so this was also 
included in the culture conditions. Finally, the use of hPLP and hP caused culture media 
clotting, thus implying the use of an anticoagulant such as heparin which was added to the 
culture medium at the concentration of 1U/mL. In summary, the experiments aiming at replacing 
FBS by human components were performed on fibronectin-coated culture vessels and in media 
containing 250 µM asc, 5% of hPLP, hPL or hP, or 10% FBS or hABS, and, for the hPLP and 
hP conditions, 1U/mL heparin. MSCs were seeded at 1x10
4
cells/cm
2
 in all conditions and 
passed every 4 days.  
Similarly to the analysis done for SP-MSC SFM, the behaviour of MSCs in DMEM-F12 
supplemented with 10% FBS (as a control), 5% hPLP, 5% hPL, 5% hP and 10% hABS was 
analysed for eight continual passages (along 28 days). 
During the first passages, MSCs in the hPLP and hP conditions acquired a shorter 
morphology and looked very bright, whereas in hPL supplemented medium were flattened and 
translucent (Figure 8A b-d). However, cells in these three conditions did not proliferate or 
survive, even with fibronectin pre-coating and asc addition. Therefore, hPLP, hPL and hP  
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Figure 8. Characterisation of MSCs cultured in hPLP, hPL, hP and hABS supplemented medium. A) 
Images of MSCs cultivated in 10%FBS (a), 5% hPLP (b), 5% hPL (c), 5% hP (d) and 10% hABS-
containing medium (e). MSCs in FBS and hABS-containing medium presented a spindle shaped or 
fibroblastoid morphology during all passages (a and e). MSCs in hPLP and hP-containing medium were 
short and bright (b-c) whereas MSCs in hPL-containing medium were flattened and translucent (d). Images 
magnification: 400x. B) Growth curves representing the cumulative cell expansion rates of MSCs cultured 
in the different types of xeno-free and in FBS-containing (MSC-FBS) medium. MSCs in hPLP, hPL, hP 
supplemented medium died after 3 passages. MSC growth in hABS and FBS-containing medium 
presented a similar cumulative growth pattern. The results represent the mean ± standard deviation of 
cumulative expansion rates (total number of cells at each passage = ratio of the total number of harvested 
cells to the total number of cells plated, multiplied by the total number of cells from the previous passage) 
of 2 MSC cell lines plated at a density of 1 x 10
4
cells /cm
2
 and grown in each medium for 8 passages. C) 
Flow cytometry immunophenotyping of MSCs expanded in hABS and MSC-FBS containing medium at 
passage 4 (P4) and passage 8 (P8). High levels of expression of the CD73, CD105, CD44 and CD90 
antigens were maintained in both types of media for 8 passages. Histograms demonstrating the 
expression of the surface antigens (red line) were plotted against isotype controls (black lines) for 
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unspecific fluorescence. The percentage of positive cells and MFI are given on top of each histogram. The 
last column is a graphical representation of the average percentage of CD73, CD90, CD44 and CD105-
positive MSCs when cultured in MSC-FBS or in hABS-containing medium for 1, 4 and 8 passages. Dots 
and bars represent the mean ± standard deviation of the results for three different MSC stem cell lines. A 
high percentage of CD73, CD105, CD44 and CD90-positive cells was maintained in hABS supplemented 
medium for up to 8 passages. 
 
 
containing media were unable to support MSCs expansion for longer than 3 passages (Figure 
8B). 
Regarding the MSCs cultured in FBS and hABS containing medium, the fibroblastic-like 
morphology was maintained with no significant differences between the two culture conditions  
(Figure8A a and e). Also, the growth curves performed showed that MSCs had a similar growth 
pattern during the 8 passages in the two types of media (Figure 8B).  
The expression of MSC surface antigens was analysed before the beginning of the 
experiment and after one, four and eight passages in FBS or hABS containing medium, the only 
conditions that sustained cell expansion for longer periods. As represented in Figure 8C, 
similarly high percentages of positive cells for the MSC markers CD73, CD105, CD44 and CD90 
were present up to passage 8 for both conditions.  
 
 
3.6. Differentiation potential varies between donors and tissue source  
  
 The multilineage potential of MSCs derived from WJ-UC and W-UC was tested by 
inducing the cells to differentiate into osteoblasts, chondrocytes and adipocytes. For this, 
commercially available differentiation kits previously described in the literature were used. 
Chondrocyte and adipocyte differentiation were induced with the StemPro® Chondrogenesis 
and Adipogenesis differentiation kit, respectively. For osteoblast differentiation the StemPro® 
osteogenesis differentiation kit, the MesenCult osteogenic stimulatory kit, MesenCult, DMEM-
F12, DMEM-KO and DMEM-LG basal media with dex, asc and β-GP addition were used. For 
adipogenic and chondrogenic differentiation only a few MSC lines were tested, whereas the 
osteogenic potential was studied more extensively and for almost all the cell lines established. 
 Cells expanded in MSC-FBS complete medium were thus seeded at 1x10
4
cells/cm
2
 and 
cultured in an appropriate media for the induction of each specific lineage (Figure 9). The 
presence of chondrocytes after 21 days of MSC culture in chondrogenic induction medium was 
investigated using Toluidine Blue O, which stains for mucopolysaccharide-rich extracellular 
matrix. Variable levels of positive staining were observed for 4 out of the 6 cell lines analysed 
(Figure 9 g-i). The adipogenic differentiation ability was evaluated by Oil Red staining for the 
detection of lipids in the vacuoles after 14 days in adipogenic induction medium. Of the 6 MSC 
lines tested, two of them exhibited high and four showed moderate adipogenic differentiation 
ability (Figure 9 d-f). No correlation was observed between chondrogenic or adipogenic 
potential and the tissue source from where the cells were derived (pWJ-UC, tWJ-UC and W-
UC). However, more cell lines would have to be tested for the results to be representative.  
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Figure 9. Multilineage capacity of MSCs isolated from peripheral (pWJ), total Wharton’s jelly (tWJ) 
and whole umbilical cord (W-UC). Representative phase contrast images of cells from pWJ, tWJ and W-
UC exposed to osteogenic (a-c), adipogenic (d-f) and chondrogenic (g-i) differentiation media. Osteogenic 
differentiation of MSCs from pWJ, tWJ and W-UC was demonstrated by staining for Alkaline Phosphatase 
(AP) activity after 14 days of culture in MesenCult Osteogenic medium (a-c). Adipogenesis was detected 
by the formation of intracytoplasmic lipid droplets stained with oil red O after 14 days in StemPro® 
Adipogenesis differentiation kit (d-f). Cells were stained with toluidine blue O to confirm chondrogenic 
differentiation after 21 days in StemPro® Chondrogenesis differentiation kit (g-i). Images magnification: 
400x.  
 
    
Osteogenic differentiation was assessed by staining for alkaline phosphatase activity 
after 14 days in osteogenic induction medium (Figure 9 a-c). Alkaline Phosphatase (AP) activity 
is characteristic of the matrix deposition phase of osteoblastic differentiation and, according to 
the literature, it is higher at around 14 days after osteogenic induction. For the study of later 
differentiation stages, mineralisation (calcium deposition) was assessed by Von Kossa or 
Alizarin Red staining. Initially, the effectiveness of the two commercially available kits and the 
different basal media with osteogenic factors was tested. Comparing the alkaline phosphatase 
activity in response to the two media we observed that the only MesenCult osteogenic 
stimulatory kit efficiently induced osteogenesis (Supplementary Figure 4). Therefore, the 
MesenCult medium was chosen as the standard condition for osteogenic differentiation. From 
all MSC lines isolated and differentiated using this protocol (n=39) only two of them showed a 
high osteogenic differentiation (Table 5). The majority of the cell lines exhibited a moderate-high 
differentiation (n=25/39) and a minority exhibited a moderate-low (n=7/39) or low (n=5/39) 
differentiation ability (Table 5). 
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Table 5: Summary of the characterisation on the osteogenic ability of the isolated MSCs and relation to 
the tissue source from which they were obtained. (L- Low; ML- Moderate-Low; MH- Moderate-High; H-
high) 
 
 
 
 
 
 
 
Interestingly, when correlating the osteogenic ability with the tissue source from which 
the cells were isolated, we observed that a higher proportion of MSC lines from the tWJ-UC, W-
UC and V-UC exhibited a high or moderate-high osteogenic potential than pWJ-UC, which 
mostly exhibited moderate-low to moderate-high osteogenic differentiation (Table 5).  
 
Gene expression during differentiation was followed RT-PCR and normalised to the 
housekeeping gene β-actin. Figure 10A shows that a decrease in expression of the MSC-
specific genes CD73, CD105 and CD90 was observed during differentiation, even though in an 
irregular manner. On the other hand, the osteogenic transcription factor Runx2, was abundantly 
expressed even in undifferentiated MSC, and this expression diminished after 14 days of 
differentiation.  
As previously mentioned, Alkaline Phosphatase (AP) activity, characteristic of the matrix 
deposition phase of osteoblastic differentiation, has been reported to be higher around 14 days 
of MSC osteogenic induction. In order to confirm the timing of the peak in AP activity in our 
specific culture conditions, AP was assayed at 6, 10, 14, and 20 days of differentiation for a high 
and moderate-high osteogenic potential MSCs (Figure 10B). In fact, for the MSC lines tested, 
weak AP enzymatic activity was detected at day 6 (Figure 10B a and e), which subsequently 
increased until around day 14 when the highest activity was detected (Figure 10B c and g), and 
finally showed fainter and more spread levels at day 20 of differentiation (Figure 10B d and h). 
As shown in Figure 11B, the differentiating cells presented a compact morphology with the 
occasional formation of protuberant masses which may be composed of osteoid matrix. AP 
activity was mainly detected in colonies composed of both AP-expressing and non-expressing 
cells. The 2 cell lines tested followed a similar staining pattern even though differing on the size 
of the positive colonies (Figure 10B). At later stages of differentiation, after 21 days in 
osteogenic medium, the formation of mineralized deposits has been described to take place. To 
assess the progression of calcium deposits AR staining was performed at 22, 29 and 36 days of 
differentiation for a MSC line with high osteogenic potential (Figure 10C). Calcium deposits 
were weakly detected at 22 days in differentiation medium, but subsequently increased until the 
36 days of differentiation (Figure 10 a-c). This high concentration of calcium deposits at 36 days 
of differentiation was also confirmed by Von Kossa staining (Figure 10C d). 
Tissue source L ML MH H 
tWJ 2 1 6 1 
pWJ 1 4 5 0 
W-UC 0 1 8 1 
V 2 1 6 0 
Differentiation ability 
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Figure 10. Characterisation of osteogenesis  along differentiation time. A) RT-PCR gene expression 
analysis of CD73, CD105, CD90, Runx2 and the housekeeping gene beta-actin (βAct) for one of the MSCs 
cell lines in MSC expansion conditions and after 7, 14 and 21 days in osteogenic differentiation culture 
conditions. B) Staining for Alkaline Phosphatase (AP) activity and calcium deposition during osteogenic 
differentiation in Mesencult Osteogenic medium. An increase in Alkaline Phosphatase activity was 
observed after 14 days of osteogenic induction, with different intensities depending on the osteogenic 
potential of the different MSCs lines: (a-d) moderate differentiating and (e-h) highly differentiating cells. AP 
activity at 6 (a,e), 10 (b,f), 14 (c,g) or 20 (d,h) days of osteogenic differentiation of the MSCs with moderate 
and high potential. C) Detection of calcium deposits by Alizarin Red staining after 22 (i), 29 (j) and 36 (k) 
and days of osteogenic differentiation or by von Kossa staining after 36 days of osteogenic differentiation 
(l). D) Representative phase contrast images of cells induced to differentiate along the osteogenic lineage 
when at different passage numbers. Staining for Alkaline Phosphatase (AP) activity after 14 days of 
differentiation was more intense for cells that were differentiated when at early passages (a,b), and 
significantly decreased when differentiation was induced in high passage number cells (c,d). Images 
magnification: 400x. 
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Figure 11. Expression profiles of MSC and osteoblast markers in cells growing in osteogenic 
medium. Flow cytometric expression analysis for the MSC cell surface antigens CD73, CD90 and CD105, 
and the osteogenic markers bone Alkaline Phosphatase (bAP) and Osteocalcin, in cells cultured in MSC 
expansion conditions (MSC-FBS medium) and 15 days after osteogenic induction (in Mesencult 
Osteogenic medium). During differentiation there is a decrease in expression of MSC markers, and the 
appearance of a population of osteocalcin and bAP-positive cells. Representative histograms 
demonstrating the expression of the surface antigens (red line) were plotted against isotype controls (black 
lines) for unspecific fluorescence. The percentage of positive cells is given on top of each histogram. 
 
 
The MSC osteogenic potential of cells at different passage numbers was also analysed. 
As can be seen in Figure 10D, the osteogenic capacity was progressively diminished in cells 
with increasing passage numbers (longer time in culture), and it was almost lost at passage 16 
(Figure 10D).   
In order to further characterise the osteogenic differentiation of MSCs, the expression of 
specific cell surface proteins was analysed by flow cytometry. As expected, after 15 days of 
differentiation the MSC markers CD73, CD90 and CD105 had significantly decreased (Figure 
11), both in terms of the number of positive cells and, in the case of CD90, in number of 
expressed molecules (which was proportional to the staining MFI). Conversely, Alkaline 
Phosphatase started being expressed at the surface of a proportion of the differentiating cells. 
Interestingly, an inverse correlation in the expression of CD90 and AP was observed, as AP-
positive cells were generally CD90-negative (Figure 11). Regarding osteocalcin, a later marker 
of differentiation expressed at the beginning of the mineralisation phase, an increase in its 
expression was only starting to be detected at this stage.  
 
3.7. hUC-MSC osteogenic ability is related to the cell density, expression levels of 
CD105 and may be dependent on cell-cell interactions 
 
The differences in osteogenic potential observed in MSCs isolated from the same tissue 
source and in similar conditions were an intriguing issue that motivated additional studies. 
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Analysis of the data related to the birth conditions or the newborns did not allow any type of 
correlation that could help to explain or predict the differential expansion and differentiation 
potential (Table 4). We therefore attempted to determine which characteristics of these cells 
could be related to or help predict the osteogenic potential, or which conditions could influence 
it. For this, the cell density, expression levels of CD105 and cell-cell interactions were analysed.  
One of the highly differentiating cell lines was initially expanded from a low cell number 
due to the poor cell recovery for this particular UC. Therefore, the effect of selecting for highly 
proliferative MSCs on the differentiation potential was investigated. For that, cells were plated at 
a low density (200cell/cm
2
) in expansion medium and 14 days later, cells from the colonies 
resulting from the more proliferative cells were harvested, analysed and induced to differentiate 
(Figure 12). The cell surface expression analysis of MSC specific markers CD73, CD105, CD44 
and CD90 showed that the percentage of cells positive for MSCs characteristic markers were 
maintained (Figure 12A), even though the MFI of CD90 highly increased for both MSC lines 
tested. These cells were then submitted to osteogenic differentiation conditions which showed 
that both MSCs with moderate and high osteogenic potential almost lost all the differentiation 
capacity (Figure 12B).    
 
Another feature that can be related to the differential osteogenic ability of MSCs is the 
expression level of CD105 and CD90, the MSC markers that showed more variations between 
cell lines with differing osteogenic abilities and in response to the culture environment. To test 
this hypothesis, osteogenic competent MSCs were stained with anti-CD105 and anti-CD90 
antibodies and the cell populations with high (CD105
high
/CD90
high
) and low levels 
(CD105
low
/CD90
low
) of the two surface proteins were sorted by FACS (Figure 13A).  After 
sorting, the cells were reseeded and were let to recover in MSC-FBS medium for 7 days, at 
which stage they were harvested and reseeded in osteogenic inducing media. Curiously, the 
analysis for AP activity and calcium deposition showed that osteogenic differentiation was 
considerably more efficient in CD105
high
/CD90
high
 than in CD105
low
/CD90
low
 MSCs (Figure 13B). 
However, it was not clear whether this effect was in response to the selection for the CD105 or 
the CD90 highly expressing population, and if it was specific to this particular cell line. 
Therefore, cell sorting was repeated but this time based only on the CD105 levels and including 
another moderately differentiating MSC line. The decision to focus on the CD105 marker, 
besides the reasons already mentioned, was related to the fact that the expression of CD105 
has been reported to decrease over time during the course of multi-lineage differentiation (Choi 
et al., 2009). After sorting, the cells were cultured in expansion conditions for 7 days and then 
their immunophenotype was analysed. In terms of percentages of the markers CD73, CD105, 
CD44 and CD90 no significant differences were observed between CD105
high
 and 105
low
, cells 
(Figure 13C). However, analysis of the MFI of MSCs markers in the two sorted populations 
showed that CD105
high 
cells had not only a higher MFI for CD105 but also for CD90 compared 
to the CD105
low
 MSCs. When the osteogenic potential of these cells was analysed, an increase 
in AP activity was once more observed in CD105
high 
MSCs, for both the cell lines (Figure 13D).    
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Figure 12. Phenotypical features and differentiation ability of MSCs cultured at low density. A) Flow 
cytometry immunophenotyping of MSCs expanded for 14 days in standard MSC-FBS medium at normal 
(1x10
4
cells/cm
2
) or low (200cells/cm
2
) plating density. No differences were observed in terms of 
percentage of the cell surface markers CD73, CD105, CD44 and CD90 but the MFI of CD90 staining 
highly increased in cells expanded at low density. Histograms demonstrating the expression of the surface 
antigens (red line) were plotted against isotype controls (black lines) for unspecific fluorescence. The 
percentage of positive cells and MFI are given on top of each histogram. B) Representative phase contrast 
images of MSCs cultured in osteogenic medium after expansion at normal (a,b,e) or low cell density 
(c,d,f,g). Staining for Alkaline Phosphatase (AP) activity after 14 days of differentiation and for calcium 
deposits by Alizarin Red staining after 21 days of differentiation considerably decreased in MSCs 
previously expanded at low density. Images magnification: 400x. 
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To determine the effect of cell-cell interaction in MSC differentiation ability, cells with 
different osteogenic potential were co-cultured in osteogenic-inducing conditions (Mesencult 
osteogenic stimulatory kit) and the resulting differentiation was assessed by staining for alkaline 
phosphatase activity. Figure 14A shows that the co-culture of one MSC line with a high 
differentiation potential with one with moderate potential results in high osteogenic 
differentiation. Equally, the co-culture of MSCs with high differentiation potential with poorly 
differentiating ones also showed high osteogenic differentiation (Figure 14B). Additionally, the 
co-culture of MSCs with a moderate and low differentiation potential produced moderate 
osteogenesis (Figure 14C). Therefore, cells with a lower propensity for osteogenic 
differentiation seem to be induced to differentiate when in the presence of more osteogenic 
prone cells. 
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Figure 13. Analysis of MSCs sorted for differential expression levels of CD105 and CD90. A) Dot plot 
showing the gates used for sorting the CD105 and the CD90 populations. B) Representative phase 
contrast images of MSCs cultured in osteogenic medium after cell sorting for high (CD90
high
/CD105
high
) 
and low levels of CD105 and CD90 (CD90
low
/CD105
low
) by FACS. Staining for Alkaline Phosphatase (AP) 
activity after 14 days of differentiation and for calcium deposits by Alizarin Red staining after 21 days of 
differentiation both showed decreased osteogenic differentiation in CD90
low
/CD105
low 
MSCs (a) and 
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increased differentiation in CD90
high
/CD105
high
 cells
 
(b). Images magnification: 400x. C) Flow cytometry 
immunophenotyping of MSCs sorted for low/high CD105 MSCs and expanded in standard MSC-FBS 
medium for one passage after sorting. No differences in percentages of CD73, CD105, CD44 and CD90 
were observed between Low/High CD105MSCs. MSCs CD105
high 
had higher levels of MFIs for CD105 
and CD90 than the MSCs CD105
-
 Histograms demonstrating the expression of the surface antigens (red 
line) were plotted against isotype controls (black lines) for unspecific fluorescence. The percentage of 
positive cells and MFI are given on top of each histogram. C) Representative phase contrast images of 
MSCs cultured in osteogenic medium after cell sorting for high (CD105
high
) or low levels of CD105 
(CD105
low
). Staining for Alkaline Phosphatase (AP) activity after 14 days of differentiation and for calcium 
deposits by Alizarin Red staining after 21 days of differentiation both showed decreased osteogenic 
differentiation in CD105
low 
MSCs (b,d,f,h) and increased differentiation in CD105
high
 cells (b,c,e,g). Images 
magnification: 400x. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Analysis of differentiation of co-cultures of cells with differential osteogenic potential. 
Equal cell numbers of two MSC lines with different osteogenic abilities were mixed and co-cultured for 14 
days in osteogenic medium, at which point differentiation was assessed by staining for Alkaline 
Phosphatase (AP) activity. Three different types of co-cultures were experimented: A) the mix of 
moderately differentiating cells (a) and highly differentiating ones (b)  resulted in co-culture (c); B) cells 
with low osteogenic potential (a) mixed with high osteogenic potential cells (b) produced co-culture (c); C) 
co-culture (c) was composed of low (a) and moderately (b) differenting MSCs. Staining for AP activity of 
the MSC co-cultures (A c, B c, C c) consistently looked more similar to the highest differentiating cell line in 
the original mixture.  Images magnification: 400x. 
 
3.8. hABS supplemented expansion medium is capable of maintaining MSC 
osteogenic potential 
 
As previously mentioned, an adequate clinically compatible culture medium should 
support MSC expansion while maintaining the essential properties, phenotype, and multilineage 
potential of these cells. Therefore, we have assessed whether cells expanded in xeno-free 
media maintained the osteogenic potential (Figure 15). MSCs with moderate to high 
differentiation potential (assessed after expansion in MSC-FBS medium), when expanded in 
SP-MSC SFM experienced a significant reduction in their osteogenic potential, as quantified by 
AP staining (Figure 15 b and e). Conversely, cells expanded in hABS supplemented media 
succeeded to maintain their osteogenic potential (Figure 15 c and f). Therefore, hABS 
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supplemented media appears to be a better choice when it is seeking for a more adequate 
clinically compatible culture medium.    
 
Figure 15. Osteogenic differentiation of MSCs expanded in xeno-free media. Representative phase 
contrast images of MSCs cultured in MesenCult osteogenic stimulatory kit after expansion for at least three 
passages in SP-MSC SFM, hABS supplemented medium or the standard MSC-FBS medium. MSCs with 
moderate to high osteogenic potential experienced a considerable decrease in AP activity after expansion 
in SP-MSC SFM (c,d) when compared to the MSC-FBS control (a,b). hABS supplemented medium 
maintained the osteogenic potential of MSCs with moderate (e) and high osteogenic potential (f). Images 
magnification: 400x. 
 
 
3.9. The human amniotic membrane is a potentially suitable carrier substrate for a 
MSC-derived osteoblastic matrix 
 
The last part of this study involved the use of human amniotic membrane as a substrate 
to support MSC osteogenic differentiation. Two types of AM processed by the CHSul Tissue 
Bank were tested: dehydrated AM on a silicone base, and AM frozen at -80ºC in 10% DMSO. 
MSCs were plated on both types of AM and, even though in both cases it was left to hydrate or 
equilibrate in culture medium for approximately 24h, the dehydrated membrane did not 
efficiently re-hydrate and so it did not allow cell adhesion. On the other hand, the frozen AM did 
support MSC adhesion, even though it was difficult to distinguish the MSCs from the AM 
constituent cells.  To resolve this difficulty, neutral red staining was performed (Figure 16A). 
This has showed that AM is completely decellularised and thus any affect produced in MSCs 
was exclusively caused by AM extracellularmatrix.  
MSCs were then plated and induced to differentiate on the AM, as cells grew on the AM 
in osteogenic differentiation medium, they started pulling and creasing it. In order to try to hold 
the AM to the culture plates these were initially pre-coated with fibronectin. However, this did 
not prevent folding. Subsequently, a teflon ring was placed on top of the AM to try to prevent its 
deformation, an approach that was reasonably successful.  
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AP staining of the AM with cells cultured in expansion medium supplemented with 10 or 
2%FBS, revealed a modest osteogenic differentiation (Figure 16B b and d) as compared to the 
negative control of AM without cells (Figure 17B f). Preliminary results of MSCs induced to 
differentiate on amniotic membrane in osteogenic inducing medium Mesencult or DMEM-F12 
with 10 or 2%FBS and the osteogenic supplements dex, asc and -GP (from Sigma) showed 
that this substrate allows identical to osteogenic differentiation (Figure 17B a and c), as was 
assessed by alkaline phosphatase activity. However, differentiation was not as efficient as for 
cells plated on plastic (Figure 17B e). Analysis of differentiation at later stages was not possible 
because of the high background obtained when performing von Kossa or Alizarin red staining in 
the negative control with only amniotic membrane (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. MSC osteogenic differentiation on human amniotic membrane. A) Images representative 
of neutral red staining of amniotic membrane (AM) only (a), MSCs plated on AM (b) and MSCs seeded in a 
plastic vessel (c) in osteogenic medium. Only the conditions in which MSCs were present stained positive 
for neutral red (b, c). B) AP staining for MSCs grown for 14 days in different culture conditions. After 14 
days in osteogenic media, AM with no added MSCs was negative for AP activity (f) while MSCs plated on 
AM (a) or in plastic plates (e) exhibited positive AP staining. AP activity of MSCs plated on AM in 
osteogenic medium with a reduced amount (2%) of FBS (c) was comparable to AP activity of MSCs in 
complete osteogenic medium (a). In MSC/FBS medium (b) and reduced MSC-FBS (2%FBS) medium (d) 
cells also showed some AP activity. Images magnification: 400x. 
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4. Discussion and Future Work 
 
The umbilical cord (UC) is a very promising mesenchymal stromal cell (MSC) source as 
cells can be easily obtained from this tissue without facing the ethical problems of embryonic 
stem cells (Can and Karahuseyinoglu, 2007). In addition, they seem to have greater expansion 
capability (Mitchell et al., 2003; Troyer and Weiss, 2008; Karahuseyinoglu et al., 2007) and 
broader potential (Mitchell et al., 2003; Wang et al., 2004; Conconi et al., 2006; Troyer and 
Weiss, 2008; Chen et al., 2009) than cells from other adult stem cell sources, such as bone 
marrow (Panepucci et al., 2004; Chen MY et al., 2009). 
Isolation of MSCs from distinct parts of the UC and the use of different methods for the 
isolation of MSCs from UC have been described (Romanov et al., 2002; Mitchell et al, 2003; 
Paneppucci et al., 2004; Wang et al, 2004; Sarugaser et al., 2005; Fong et al., 2007; 
Karahuseyinoglu et al, 2007; Secco et al., 2008; Seshareddy et al. 2008; Ishige et al, 2009; 
Zeddou et al., 2010). In this work, we successfully established 51distint human MSC lines from 
26 UC donors. To determine an efficient isolation procedure from different tissue source we 
obtained MSCs from 13 peripheral Wharton’s Jelly (pWJ), 14 total Wharton’s Jelly (tWJ), 15 
Whole umbilical cord (W-UC) and 12 vessels (V-UC) tissue. We found that a good balance 
between tissue dissociation and cell yield was obtained by performing a mechanical disruption 
of the WJ, vessels and whole cord tissue and performing 3 to 4 hour of enzymatic digestion with 
collagenase and hyaluronidase. For the isolation of tWJ, an initial 1 hour enzymatic digestion 
was performed to allow removal of the UC vessels, before following a procedure similar to the 
remaining tissues. 
Cell suspensions immediately after isolation contained a mixture of cell types with 
variable expression of the markers analysed. Cells from W-UC present higher levels of 
hematopoietic markers than WJ-UC probably due to blood contamination from the vessels. 
Expression of the MSCs characteristic markers CD73, CD44, CD90 and CD105 highly 
increased from the time of the isolation to the first passage. This may be because the culture 
conditions induced the expression of those proteins, selected for MSCs, or may be related to a 
lower proliferation of the other cell types. Some embryonic stem cells markers have been 
reported to be present in MSCs such as SSEA-4 and alkaline phosphatase (Fong et al., 2007). 
In the present study a subpopulation of MSCs lines from different tissue source expressed the 
primitive stem cell marker SSEA-4 but not alkaline phosphatase. The presence of SSEA-4 
suggests that these cells may possess certain embryonic stem cells properties. However, other 
study demonstrated that this early embryonic glycolipidic antigen expression was restricted to 
BM-MSCs and not expressed in UC-MSCs (Zeddou et al., 2010).  Thus, despite the lack of 
alkaline phosphatase, this profile indicates an evolutionary proximity between these cells and 
embryonic stem cells (Fong et al., 2007). Primary cultures obtained from different tissue sources 
demonstrated a variable morphology with some clusters of cells with typical endothelial 
morphology. Our culture conditions may thus be inappropriate for endothelial cells since after 
the first passage the clusters disappeared, as had also been described by other authors 
(Romanov et al., 2002; Secco et al., 2007). At the time of the first passage, more cells per gram 
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of W-UC tissue were systematically obtained compared to tWJ-UC tissue. One possible 
explanation is that the mixture of cell types obtained from the different parts of UC might 
potentiate cell adhesion and proliferation at this phase. After passaging, no major differences in 
the cell cultures were observed for the different tissue sources or isolation methods. In fact, the 
cultures became more homogeneous with continual passages.  
For MSC expansion we used DMEM-F12 based media, a choice that was based in the 
work of Nekanti et al. (2010) who demonstrated that media with higher glucose concentrations 
sustain a greater growth potential of WJ-MSCs, maintain the typical spindle-shaped fibroblast-
like morphology until later passages, and prevent senescence in early and later passages. 
However, the optimum basal medium, and in particular the ideal glucose content, for MSC 
expansion is not consensual and some reports argue that a low-glucose content is more 
appropriate (Sotiropoulou et al., 2006). In fact, the most common and, according to many 
studies, more adequate, basal medium for MSC culture is the low glucose α-MEM (Both et al., 
2007; Chen et al., 2009; Sotiropoulou et al., 2006), even though other studies show opposite 
results (Pal et al., 2009; Nekanti et al., 2010). This inconsistency may be due to source-related 
variations, other cell type specific or culture conditions particularities, or differences between 
short-term and prolonged cultures, as suggested by Pal and colleagues (2009). Therefore, the 
best culture conditions must be found for each particular system. In this work, the isolated cells 
could be successfully expanded, while maintaining their essential characteristics, in a culture 
medium composed of DMEM-F12 with glutamine and 10% FBS. MSCs morphology from 
different lines in this medium remained relatively homogeneous, predominantly with spindle-
shaped fibroblast-like cells, until late passages. At high passages cells changed to a more 
stretched and branched morphology. MSCs from tWJ and W-UC showed similar growth pattern 
up to 12 passages, but pWJ showed a less proliferative profile in late passages. In early and 
late passages, MSCs remained highly positive for CD73, CD105, CD44 and CD90 and negative 
for CD19, CD14, CD45, CD34 and HLA-DR, despite some irregular values of CD73 and CD105 
MFI in higher passages.  
 
Due to the increasing interest in the use on MSCs in regenerative medicine, active 
research is under way in search for clinically compatible culture media (Klyushnenkova et al., 
2005; Kode et al., 2009). We have thus attempted to establish xeno-free culture conditions for 
the expansion and differentiation of the isolated UC-MSCs. Firstly, we used the commercial 
StemPro MSC serum free medium. Previous studies had described that this medium does not 
sustain cell adhesion to plastic without the use of a substrate such as fibronectin (Agata et al., 
2009; Chase et al., 2010; Hartmann et al., 2010), a fact that is immediately disadvantageous. 
Therefore, Hartmann and colleagues successfully tried to overcome this issue by adding 2% of 
human serum (Hartmann et al., 2010). In our study only 1 out of 6 MSC lines was successfully 
isolated directly in this media, a success rate inferior to other studies (Agata et al., 2009; 
Hartmann et al., 2010), what can be due to differences in tissue source or isolation method. 
During expansion, despite some differences in terms of morphology, the growth rate and 
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immunophenotype of MSCs in SP-MSC SFM were comparable to FBS-containing medium for 
the same seeding density, except for the expression of the CD105 antigen. The number of 
CD105 positive MSCs in this serum free medium decreased with time in culture, in opposition to 
the observations of Agata and colleagues that had reported an increase of CD105 MFI in this 
media (Agata et al., 2009). CD105, also known as Endoglin, is a type I membrane glycoprotein 
part of the TGF-β receptor complex (Barbara et al., 1999; Blanco et al., 2005). In addition to 
MSCs, it is expressed in endothelial cells, activated macrophages, chondrocytes, fibroblasts, 
and smooth muscle cells (Fonsatti and Maio, 2004). It has been suggested that Endoglin plays 
an important role in the modulation of the activity of the different branches of the TGF-β 
signalling pathway, therefore determining the biological response to growth factors belonging to 
this superfamily (Letamendía et al., 1998; Lebrin et al., 2004; Blanco et al., 2005; Scherner et 
al., 2007; Ishibashi et al., 2010). Therefore, the decrease in CD105 levels in SP MSC SFM may 
be related to the modulation of signalling in response to the TGF-β1 present in this medium.  
In addition to this commercial serum-free medium, other culture conditions in which FBS 
was replaced by human components were tested. Human plasma (hP), platelet lysate (hPLP or 
hPL), and AB serum (hABS) have been previously reported to support MSC expansion in vitro 
(Doucet et al., 2005; Müller et al., 2006; Kocaoemer et al., 2007; Schallmoser et al., 2007; 
Bieback et al., 2009). Preliminary results indicate that in our case hPLP, hPL and hP 
replacements are not as efficient at supporting MSCs proliferation and viability compared to 
FBS, even with fibronectin pre-coating and the addition of 250µM asc. Adding ascorbic acid to 
the culture conditions was shown by others (Choi KM et al., 2008; Potdar and d’Sousa, 2010), 
and confirmed by us, to enhance proliferation while preserving the MSC phenotype and 
differentiation potency. However, this was not effective in these culture conditions, and the cells 
progressively died and disappeared from culture at the third passage. The poor performance of 
MSCs in hPLP medium had also been reported in other studies (Kocaoemer et al., 2007; 
Schallmoser et al., 2007), and can be related with the platelet-lysate preparation method where 
centrifugation at high acceleration clears the platelet membranes, which release small 
membrane vesicles that have an additional mitogenic effect (Kocaoemer et al., 2007). This may 
have caused the observed decreased proliferative effect of MSCs. However, platelet-lysate 
containing medium supplemented with bFGF has been shown to improve MSC expansion 
(Yamaguchi et al., 2002; Doucet et al., 2005), something that should be experimented in future 
work.   
Most studies concerning the use of human serum as a supplement substitute for FBS 
focus on the use of autologous serum (Yamamoto et al., 2003; Mizuno et al., 2006). However, 
this approach can be limiting in the quantity and quality of the serum for the MSC expansion, 
especially for some pathological conditions (Kocaoemer et al., 2007). Alternatively, a pool of 
human allogeneic AB serum would provide a more abundant and immediately available source. 
We show here that MSCs expanded in a hABS supplemented medium had similar morphology, 
proliferation rate, viability and immunophenotype as in FBS-containing medium. Some groups 
had already achieved similar results using hABS, even though sometimes also requiring the 
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addition of bFGF (Yamaguchi et al., 2002; Kocaoemer et al., 2007), while others have reported 
death of the cells at the first passage (Shahdadfar et al., 2005). In this study, the good 
performance of MSCs expansion in hABS-supplemented medium indicates that, of the FBS 
substitutes analysed, this medium is the most promising xeno-free culture condition. 
 
As proposed by The International Society for Cellular Therapy, MSCs should have the 
ability to differentiate in vitro into cells of the osteoblastic, adipogenic and chondrogenic 
lineages. A heterogenic differentiation potential was observed between MSCs lines, especially 
between pWJ and tWJ tissue source. The reason for this inconsistency is still unclear. One 
possibility is that WJ cells made accessible by the two different methods have distinct 
potentials. In the case of tWJ, the isolation method involved enzymatic digestions for the 
removal of the vessels and thus enabling the isolation not only of the superficial layer of the WJ 
but also the inner WJ cells surrounding the vessels. Also, the difficulty in identifying and 
removing all the vessel pieces when using this method may allow their accidental inclusion in 
the final dissociated tissue. In fact, some studies have suggested that MSCs in the UC are 
preferentially located in the perivascular zone, as cells from this region show a higher  in vitro 
expansion and differentiation potential (Suragaser et al., 2005), or as part of the vessels, with 
artery-derived cells exhibiting a greater osteogenic potential (Ishige et al., 2009).  
During osteogenic differentiation, MSCs exhibited a progressive decrease in gene 
expression of CD73, CD105, CD90 and Runx2. Regarding protein expression of cell surface 
antigens, the majority of the cells stopped expressing the MSC surface marker CD105, while 
the CD73 and CD90 antigens only experienced a moderate reduction. Simultaneously, specific 
osteogenic markers, such as osteocalcin and alkaline phosphatase started to be detected. 
Importantly, alkaline phosphatase was present mainly at the surface of CD90
low
 or negative 
cells. However, the proportion of AP-positive cells detected by flow cytometry was significantly 
lower than the enzymatic alkaline phosphatase activity detected at the same stage of 
differentiation. This may be due to an inefficiency of the antibodies used, or because the AP is 
being secreted and therefore only transiently expressed at the cell surface. Similarly, 
osteocalcin expression by flow cytometry was poorly detected, what may mean that it is not yet 
strongly expressed at this stage (as it is a later marker of differentiation characteristic of the 
beginning of mineralisation), or that, since it is generally an intracellular protein, cell surface 
detection was not adequate. Given that neither AP nor osteocalcin seem to be good cell surface 
markers of differentiation for flow cytometry detection, it would desirable to find such a 
phenotypic marker, such as Cadherin 11 (CDH11), or OB-cadherin, that seems to be a good 
candidate for this role (Cheng et al., 1998; Lecanda et al., 2000; Kii et al, 2004).  
 
 The differences observed in osteogenic potential between MSCs from the same tissue 
source were an intriguing issue for us. Initially, we have analysed whether this tendency was 
related to specific clinical parameters at the time of birth (gestational stage and mother’s age) 
and isolation method but no correlation was found. We therefore attempted to determine which 
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characteristics of these cells could be related to or help predict the osteogenic potential, or 
which conditions could influence it.  
Since some MSCs with high osteogenic potential experienced a low cell density during 
isolation due to low dissociation efficiency, we firstly expanded MSCs from low density cultures. 
This should select for clonal cells which could be at a more undifferentiated stage. However, 
MSCs that initially showed a moderate to high osteogenic potential, after low density almost 
completely lost the differentiation potential suggesting. Some authors affirmed that the fact of 
MSC culture became homogenous after several passages at high density may cause the loss of 
their osteogenic differentiation (Colter et al. 2001; Smith et al., 2004). In contrast, low plating 
densities seems to maintain heterogeneous cell morphologies and thus favour differentiation 
(Colter et al., 2001).      
 Subsequently, the relation between the expression of MSC specific antigens and the 
differentiation stage or propensity was assessed. As had already been reported by others (Jin et 
al., 2009) we have observed that the expression of MSC markers was reduced during 
osteogenic differentiation. Most interesting was the decrease in CD105 expression, practically 
disappearing at 14 days of differentiation, and the appearance of alkaline phosphatase marker 
at the cell surface of CD90
low
 or negative cells. Also, the expression levels of these markers 
partially correlated with the osteogenic ability of the cell lines and varied in response to the 
culture environment. Therefore, when performing the isolation of the CD105
low
/CD90
low
 cell 
population by cell sorting and subsequently differentiating it, we expected to obtain increased 
osteogenic differentiation. However, differentiation of the CD105
high
/CD90
high 
sorted population 
produced higher AP activity and calcium deposits compared to both the CD105
low
/CD90
low 
and 
to the non-sorted MSCs population. The subsequent analysis, following a similar approach but 
focusing particularly on the expression of CD105, was based on the fact that higher 
differentiating MSC lines expressed lower levels of this antigen, and that CD105 expression had 
been reported to decrease over time during the course of multi-lineage differentiation (Choi et 
al., 2009). An increase in the osteogenic potential of CD105
high
 MSCs was again obtained. 
Therefore, MSCs with high expression levels of CD105 seem to be more prone for osteogenic 
differentiation. This observation is in agreement with the study of Jarocha and who reported that 
CD105
high
 BM-MSC had an enrichment in molecular markers of early osteogenic progenitors 
(Jarocha et al., 2008). In summary, increased levels of CD90 and CD105, in particular the latter, 
seem to be predictive of an increased osteogenic propensity, and may be related to a more 
undifferentiated state. In addition to these, the expression levels of CD146 have also been 
suggested to correlate with the differentiation potential of MSC-UC and thus should also be 
investigated (Baksh et al., 2007).  
Finally, we addressed the question of whether the osteogenic differentiation ability of a 
MSC was a cell autonomous property or was conditioned by the environment and the 
neighbouring cells. The co-culture of cells with different osteogenic potential showed that the AP 
activity of cells with lower differentiation ability was enhanced when co-cultured with higher 
differentiating ones. This approach needs to be studied in more detail, but it seems that either 
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growth factors released to the medium by the cells with higher differentiation potential or the 
cell-to-cell contact are responsible for the increase in osteogenic potential in MSCs. 
Therefore, some experiments should be performed in the future, in order to understand 
the mechanism behind the modulation of osteogenic differentiation in co-cultures. For example, 
conditioned medium experiments, in which the culture medium from MSCs with high and low 
osteogenic abilities is exchanged can elucidate whether this osteogenic modulation is mediated 
by secreted factors whether it requires cell-to-cell contact. 
 
As previously mentioned, an adequate clinically compatible culture medium should, 
support MSC expansion while maintaining the essential properties, phenotype, and multilineage 
potential of these cells. Therefore, the osteogenic potential of the cells expanded in different 
xeno-free media (SP-MSC SFM and hABS) were tested but satisfactory results, were obtained 
only for the commercial hABS supplemented medium, which succeeded to maintain their 
osteogenic potential. The low osteogenic potential of MSCs expanded in SP-MSC SFM can be 
related to the decrease in the CD105 antigen during cell expansion, since the CD105
low
 
population has already been shown to have lower osteogenic potential. Published studies are 
not consensual on the effect of SP-MSC SFM in osteogenic differentiation. Whereas Chase et 
al., reported the maintenance of the osteogenic potential in BM-MSCs expanded in this medium 
(Chase et al, 2010), Agata and colleagues observed a decrease in AP activity similar to ours 
(Agata et al., 2009). Moreover, Hartmann et al., also described the maintenance of osteogenic 
potential in this medium but requiring the addition of 2% human serum for enhanced results 
(Hartmann et al., 2010). Regarding the hABS supplement, the maintenance of MSC osteogenic 
capacity was also observed in the studies of Kocaoemer and colleagues (Kocaoemer, kern, 
Kluter et al., 2007).   
Therefore, hABS supplemented medium seems to be a good xeno-free supplement for 
MSC expansion, as it promotes cell proliferation, maintains high levels of expression of the 
specific MSC markers and retains the potential for osteogenic differentiation. However, further 
experiments should be performed for the complete validation of the hABS medium, such as the 
direct isolation of MSCs from the UC in these conditions and the assessment of multilineage 
differentiation. Besides that, a xeno-free differentiation medium must also be established and 
thus a hABS supplemented medium with the osteogenic factors dex, asc and -GP, and 
possibly with the addition of BMPs or TGF-β growth factors should be tested (Centrella et al., 
1991; Lecanda et al., 1997; Cheng et al., 2003; Kanaan and Kanaan, 2006)..  
 
Differentiation is also determined by the substrate on which cells are (Salasznyk et al., 
2004; Cool and Nurcombe, 2005; Chastain et al., 2006) and, in particular, fibronectin has been 
reported to enhance cell adhesion and differentiation (Hidalgo-Batisda and Cartmell, 2010). 
Even though in this study fibronectin pre-coating did not have any effect in osteogenic 
differentiation efficiency, other substrates such as collagen (Salasznyk et al., 2004) and, more 
interestingly, amniotic membrane, could be suitable substrates for differentiation. The use of 
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human amniotic membrane as a support material for MSC osteogenic differentiation would help 
overcoming the cell dissociation and disruption of the matrix and of the cell network.  
The analysis of the use of AM for this purpose has been hindered by the difficulty in 
identifying cells on the membrane, to prevent its creasing and to assess cell differentiation. 
Staining with neutral red helped to distinguish the MSC live cells from the apoptotic AM cells 
and the use of Teflon rings, a technique previously used in another study (Furie et al., 1984), 
was an efficient option to secure AM to the tissue culture plate. Moreover, frozen AM was 
preferentially used in our studies since it supports MSC adhesion and proliferation more 
efficiently than dehydrated AM. For the evaluation of MSC osteogenic differentiation on AM, 
staining for AP activity was the chosen method since Kossa and Alizarin red staining assay 
produced high background.  
AP activity of MSCs seeded on AM in osteogenic medium showed comparable results 
with MSCs seeded on plastic. However, a basal osteogenic induction was observed in the 
MSCs plated on AM in the expansion medium. Therefore, there is the possibility that the 
acellular AM has some inherent properties capable of inducing osteogenesis, as also previously 
reported by Samandari et al. (2011). This capability could be due to the combination of growth 
factors described to be present in AM (Koizumi et al., 2000; Valladares et al., 2010). 
Consequently, a reduction in the FBS content from 10% to 2% was assessed to evaluate the 
potential of AM intrinsic factors to sustain osteogenic differentiation. AP activity analysis 
suggested that the AM could support osteogenic differentiation in a reduced serum environment 
what further increases the suitability of membrane as a scaffold to support osteogenic 
differentiation.  Once more, it would be important to test the use of hABS-containing medium for 
MSC osteogenic differentiation on AM.  
 
In conclusion, in this study an efficient method was established for the isolation of cells 
from the human UC stroma, a promising stem cell source especially due to its easy and non-
invasive acquisition. In particular, tWJ-UC seems to be the most adequate tissue source within 
the UC, given the relatively high efficiency and reproducibility of the isolation, and the fact that it 
contains mostly free of other contaminant cell types. Also, tWJ-UC MSCs possess all the 
defining MSC characteristics and exhibit good differentiation ability. 
 Moreover, although additional studies are needed for the improvement of the MSC 
culture conditions, the xeno-free hABS-supplemented medium succeeded to maintain UC-MSC 
proliferation without compromising their morphological and immunophenotypical features, nor 
the ability for osteogenic differentiation. The applicability of this supplement for osteogenic 
differentiation should be subject of future analysis. 
With this study we were also able to unravel some aspects of MSC osteogenic 
differentiation, even though many others are still unclear. According to our data, the isolation 
method and tissue source do influence MSC osteogenic differentiation even though not in a 
very consistent manner. Additionally, enhanced MSCs osteogenesis was possible by CD105
high
 
population enrichment or by MSCs co-culture. The mechanism responsible for these effects 
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should be investigated. Finally, additional studies should be performed on MSC differentiation 
on amniotic membrane, since the AM seems to be a promising substrate for the production of 
an osseous matrix suitable for transplantation.  
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Supplementary Figure 1. Description of total Warthon’s Jelly-derived MSCs isolation method. The 
umbilical cords (UCs) were first washed in Hanks’ balanced salt solution with antibiotics and then cut into 
2-3cm pieces (a). To obtain MSCs from total Warthon’s Jelly (tWJ) each cord piece was cut open 
lengthwise (b) and the inner part was faced down and subjected to an initial 1h enzymatic solution (c) 
composed of collagenase and hyaluronidase. After this digestion, the wharton’s jelly tissue became softer 
and the removal of arteries and veins was allowed (d). The tWJ tissue was then cutted into small 
fragments (e) and submitted to 4 hours of enzymatic digestion (f). After the second digestion, the cell 
clumps were cultured in expansion medium. 
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UC nº Tissue Source Isolation Method Isolation Efficiency 
1 pWJ Mechanical method: cut WJ around the 
vessels, and then chopped it into small  
pieces; resuspended the pieces in 
MSC/FBS  
medium and plated them straight after. 
Isolated cells adhered to 
the plate but bigger 
pieces did not; bacterial 
contamination after 1st 
passage. 
2 pWJ Cut WJ around the vessels and then 
digested for 18h in 0.2, 0.8 or 2 mg/ml 
Collagenase XI (in DMEM:F12 medium 
without FBS); washed in PBS and plated 
cells in MSC/FBS medium. 
Better efficiency for the 
0.2 and 0.8 mg/ml 
collagenase. Some cells 
only adhered 3 to 5 days 
later. 
3 pWJ Washed in PBS with antibiotics; cut WJ 
around the vessels, then in small pieces 
and digested ≈20h in 0.5mg/ml 
Collagenase XI 
Some adherent cells but 
still a significant 
percentage floating. 
4 pWJ Washed in PBS with antibiotics; cut WJ 
around the vessels, then in small pieces 
and digested ≈16h in 0.5mg/ml 
Collagenase XI; 30min Tryple digestion, 
washed and plated. 
Good efficiency, a lot 
adherent cells on the day 
after.   
5 tWJ Cut UC into ~2-3 cm segments, then cut 
lengthwise and placed with inner part down 
in enzymatic solution (0.5mg/ml 
collagenase and 100U/ml hyaluronidase) 
for 1h; vessels were then removed and the 
remaining WJ digested for another hour in 
the same enzymatic solution; the digested 
tissue was washed in PBS and further 
digested in Tryple for 20min. 
Still very big pieces that 
did not adhere; 
“contamination” with red 
blood cells; low 
efficiency. 
6 pWJ Cut WJ around the vessels, then into small 
pieces and digested ≈16h in 0.5 mg/ml 
collagenase and 100U/ml hyaluronidase; 
after digestion, the cells were passed 
through a cell strainer to remove 
undigested tissue before plating in 
MSC/FBS medium. 
Good efficiency; high 
number of single cells 
and % of viable adherent 
cells. 
7 pWJ Cut WJ around the vessels, then into small 
pieces, and digest ≈19h in 0.5mg/ml 
Collagenase XI+50U/ml hyaluronidase; 
20min Tryple digestion. 
Good efficiency; high 
number of single, 
adherent cells. 
8 tWJ Open cord pieces, place with interior part 
down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 1h; strip off and discard 
vessels; cut remaining tissue in small 
pieces and digest for 2 more hours; 
undigested pieces were filtered out with a 
cell strainer before plating the cells in 
MSC/FBS medium. 
Low efficiency; few single 
cells (not enough 
digestion) and only a % 
of them adhered.   
9 pWJ Cut WJ around the vessels, then into small 
pieces, and digested ≈17h in 0.5mg/ml 
Collagenase XI+100U/ml hyaluronidase; 
the day after, washed and plated cells in 
MSC/FBS medium. 
Good efficiency; good 
tissue dissociation and 
high cell viability. 
10 pWJ/tWJ pWJ: Cut WJ around the vessels, then into 
small pieces, and digested ≈4h in 0.5mg/ml 
Collagenase XI+100U/ml hyaluronidase. 
tWJ:  Open cord pieces, place with interior 
part down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 1h; strip off and discard 
vessels; cut remaining tissue in small 
pieces and digest for 4 more hours; 
undigested pieces from both tissues were 
filtered out with a cell strainer before plating 
the cells in MSC/FBS medium.    
pWJ: low efficiency; few 
adherent cells and high 
variable cell morphology; 
low cell viability. 
tWJ: very low efficiency;  
few adherent cells and 
very low cell viability. 
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11 tWJ Open cord pieces, place with interior part 
down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 45min; strip off and 
discard vessels; cut remaining tissue in 
small pieces and digest for 3 more hours; 
undigested pieces were filtered out with a 
cell strainer before plating the cells in 
MSC/FBS medium. 
Good efficiency; good 
tissue dissociation and 
high cell viability. 
12 pWJ /W/V pWJ: cut WJ around the vessels, then into 
small pieces, and digested ≈4h in 0.5mg/ml 
Collagenase XI+100U/ml hyaluronidase. V: 
open cord pieces, place with interior part 
down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 1h; strip off vessels and 
the remaining tissue discard; Cut vessels 
tissue into small pieces and digest for 4 
more hours; W: cut a cord piece with 2-3cm 
and digest for 4 hours. Single cells and 
undigested pieces from all tissues were 
directly plated in MSC/FBS medium.    
pWJ: low efficiency; few 
adherent cells and high 
variable cell morphology; 
low cell viability. 
W: very high efficiency; 
high number of single 
cells and % of viable 
adherent cells.  
V: good efficiency; high 
number of adherent cells 
clumps. 
13 pWJ /W/V pWJ: cut WJ around the vessels, then into 
small pieces, and digested ≈4h in 0.5mg/ml 
Collagenase XI+100U/ml hyaluronidase. V: 
open cord pieces, place with interior part 
down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 1h; strip off vessels and 
the remaining tissue discard; Cut vessels 
tissue into small pieces and digest for 4 
more hours; W: cut a cord piece with 2-3cm 
and digest for 4 hours. Single cells and 
undigested pieces from all tissues were 
directly plated in MSC/FBS medium.    
pWJ: good efficiency; 
some adherent cells and 
high variable cell 
morphology.  
W: very high efficiency; 
high number of cells 
clumps and % of viable 
adherent cells.  
V:  good efficiency; high 
number of adherent cells 
clumps. 
14 pWJ /W/V pWJ: cut WJ around the vessels, then into 
small pieces, and digested ≈4h in 0.5mg/ml 
Collagenase XI+100U/ml hyaluronidase. V: 
open cord pieces, place with interior part 
down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 45min; strip off vessels 
and the remaining tissue discard; Cut 
vessels tissue into small pieces and digest 
for 3 more hours; W: cut a cord piece with 
2-3cm and digest for 4 hours. Single cells 
and undigested pieces from all tissues 
were directly plated in MSC/FBS medium.    
pWJ: low efficiency; 
bacterial contamination 
after few days in culture. 
W: good efficiency; 
Several cells clumps and 
good % of viable 
adherent cells.  
V:  good efficiency; some 
adherent cells clumps. 
15 pWJ /W/V pWJ: cut WJ around the vessels, then into 
small pieces, and digested ≈4h in 0.5mg/ml 
Collagenase XI+100U/ml hyaluronidase. V: 
open cord pieces, place with interior part 
down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 45min; strip off vessels 
and the remaining tissue discard; Cut 
vessels tissue into small pieces and digest 
for 3 more hours; W: cut a cord piece with 
2-3cm and digest for 4 hours. Single cells 
and undigested pieces from all tissues 
were directly plated in MSC/FBS medium. 
pWJ: good efficiency; 
some adherent cells. Low 
cell viability. 
W: very high efficiency; 
high number of single 
cells and % of viable 
adherent cells. Some 
“contamination” with red 
blood cells;  
V:  good efficiency; high 
number of adherent cells 
clumps. Higly  
“contaminated” culture 
with red blood cells; 
16 tWJ/W/V tWJ and V:  open cord pieces, place with 
interior part down on a petri dish with 
enzymatic solution (0.5mg/ml 
collagenase+100U/ml hyaluronidase) for 
1h; cut strip off vessels and the remaining 
tWJ: low efficiency; few 
adherent cell and low cell 
viability. 
W: very high efficiency; 
high number of single 
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tissue into small pieces and digest for 4 
more hours; W: cut a cord piece with 2-3cm 
and digest for 4 hours. Single cells and 
undigested pieces from all tissues were 
directly plated in MSC/FBS medium. 
cells and % of viable 
adherent cells.  
V:  good efficiency; high 
number of adherent cells 
clumps. 
17 tWJ/W/V tWJ and V:  open cord pieces, place with 
interior part down on a petri dish with 
enzymatic solution (0.5mg/ml 
collagenase+100U/ml hyaluronidase) for 
1h15min; cut strip off vessels and the 
remaining tissue into small pieces and 
digest for 3 more hours; W: cut a cord 
piece with 2-3cm and digest for 3 hours. 
Single cells and undigested pieces from all 
tissues were directly plated in MSC/FBS 
medium. 
tWJ: low efficiency; few 
adherent cell and low cell 
viability. 
W: low efficiency; few % 
of viable adherent cells.  
V:  Low efficiency; few 
number of adherent cells 
clumps. 
18 pWJ/W pWJ: cut WJ around the vessels, then into 
small pieces, and digested ≈3h in 0.5mg/ml 
Collagenase XI+100U/ml hyaluronidase.  
W: cut a cord piece with 2-3cm and digest 
for 3 hours. Single cells and undigested 
pieces from all tissues were directly plated 
in MSC/FBS medium.  
pWJ: good efficiency; 
some adherent cells. Low 
cell viability. 
W: high efficiency; high 
number of single cells 
and % of viable adherent 
cells.  
19 tWJ/W/V tWJ and V: open cord pieces, place with 
interior part down on a petri dish with 
enzymatic solution (0.5mg/ml 
collagenase+100U/ml hyaluronidase) for 
1h15min; cut strip off vessels and the 
remaining tissue into small pieces and 
digest for 3 more hours; W: cut a cord 
piece with 2-3cm and digest for 4 hours. 
Single cells and undigested pieces from all 
tissues were directly plated in MSC/FBS 
medium. 
tWJ: low efficiency; few 
adherent cell and low cell 
viability. 
W: very high efficiency; 
high % of viable adherent 
cells.  
V:  high efficiency; high 
number of adherent cells 
clumps. 
Some  “contamination” 
with red blood cells in all 
cultures; 
20 tWJ/W/V tWJ and V: open cord pieces, place with 
interior part down on a petri dish with 
enzymatic solution (0.5mg/ml 
collagenase+100U/ml hyaluronidase) for 
1h30min; cut strip off vessels and the 
remaining tissue into small pieces and 
digest for 3 more hours; W: cut a cord 
piece with 2-3cm and digest for 4 hours. 
Single cells and undigested pieces from all 
tissues were directly plated in MSC/FBS 
medium. 
tWJ/ W/ V: good 
efficiency; some adherent 
cell and good cell 
viability.  
Some  “contamination” 
with red blood cells in all 
cultures; 
21 tWJ/W/V tWJ and V: open cord pieces, place with 
interior part down on a petri dish with 
enzymatic solution (0.5mg/ml 
collagenase+100U/ml hyaluronidase) for 
1h15min; cut strip off vessels and the 
remaining tissue into small pieces and 
digest for 3 more hours; W: cut a cord 
piece with 2-3cm and digest for 4 hours. 
Single cells and undigested pieces from all 
tissues were directly plated in MSC/FBS 
medium. 
tWJ/ W/ V: Very high 
efficiency; a lot of 
adherent cell and very 
high cell viability.  
 
22 tWJ/W/V tWJ and V: open cord pieces, place with 
interior part down on a petri dish with 
enzymatic solution (0.5mg/ml 
collagenase+100U/ml hyaluronidase) for 
1h; cut strip off vessels and the remaining 
tissue into small pieces and digest for 3 
more hours; W: cut a cord piece with 2-3cm 
and digest for 4 hours. Single cells and 
undigested pieces from all tissues were 
directly plated in MSC/FBS medium. 
tWJ/W: good efficiency; 
some number of cell 
clumps adherent. 
V:  low efficiency; low 
number of adherent cells 
clumps. 
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23 tWJ/W/V tWJ and V: open cord pieces, place with 
interior part down on a petri dish with 
enzymatic solution (0.5mg/ml 
collagenase+100U/ml hyaluronidase) for 
1h; cut strip off vessels and the remaining 
tissue into small pieces and digest for 3 
more hours; W: cut a cord piece with 2-3cm 
and digest for 4 hours. Single cells and 
undigested pieces from all tissues were 
directly plated in MSC/FBS or StemPro 
serum free medium (only for tWJ and W).  
tWJ: very low efficiency; 
very low adherent single 
cell in MSC/FBS medium. 
None adherent cells in 
SP medium.   
W: very high efficiency; 
high % of viable adherent 
cells. None adherent cells 
in SP medium. 
V:  very low efficiency; 
very low number of 
adherent single cells. 
Some  “contamination” 
with red blood cells in all 
cultures;  
24 tWJ/W/V tWJ and V: open cord pieces, place with 
interior part down on a petri dish with 
enzymatic solution (0.5mg/ml 
collagenase+100U/ml hyaluronidase) for 
1h; cut strip off vessels and the remaining 
tissue into small pieces and digest for 3 
more hours; W: cut a cord piece with 2-3cm 
and digest for 4 hours. Single cells and 
undigested pieces from all tissues were 
directly plated in MSC/FBS or StemPro 
serum free medium (only for tWJ and W). 
tWJ: low efficiency; 
bacterial contamination 
after few days in culture 
in MSC/FBS medium. 
None adherent cells in 
SP medium.   
W: Good efficiency; good 
% of viable adherent 
cells. Some adherent 
cells in SP medium. 
V:  Good efficiency; good 
number of adherent cells 
clumps.  
25 tWJ/W tWJ: open cord pieces, place with interior 
part down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 1h15min; discard strip 
off vessels and cut the remaining tissue 
into small pieces and digest for 1 more 
hours; W: cut a cord piece with 2-3cm and 
digest for 2 hours. Single cells and 
undigested pieces from all tissues were 
directly plated in MSC/FBS or StemPro 
serum free medium. 
tWJ: low efficiency; big 
few adherent cell clumps 
in MSC/FBS medium. 
None adherent cells in 
SP medium.   
W: Good efficiency; good 
% of viable big adherent 
cells clumps. None 
adherent cells in SP 
medium. 
 
26 tWJ/W tWJ: open cord pieces, place with interior 
part down on a petri dish with enzymatic 
solution (0.5mg/ml collagenase+100U/ml 
hyaluronidase) for 1h15min; discard strip 
off vessels and cut the remaining tissue 
into small pieces and digest for 3 more 
hours; W: cut a cord piece with 2-3cm and 
digest for 4 hours. Single cells and 
undigested pieces from all tissues were 
directly plated in MSC/FBS medium. 
tWJ/W: good efficiency; 
good % number of 
adherent single cell. 
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Supplementary Figure 2. MSC markers for different tissue source expanded in standard MSC-FBS 
medium in high and low passages. Graphical representation of the percentage of positive MSCs 
characteristic markers from different tissue source in high and low passages. High levels of CD44, CD73, 
CD90 and CD105 antigens were maintained in high and low passages regardless of MSCs tissue source. 
Constant low levels of CD34, CD45, HLA-DR were observed along MSCs passages from all tissue 
sources. Identical shaped symbols represent results from the same UC donor. 
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Supplementary Figure 3. Characterisation of MSCs cultured in MSC/FBS medium supplemented 
with ascorbic acid. A) Growth curves representing the cumulative cell expansion rates of MSCs cultured 
in FBS-containing medium with (MSC-FBS+asc –violet line) or without ascorbic acid (MSC-FBS –blue 
line). Total number of cells at each passage was calculated as the ratio of the total number of harvested 
cells to the total number of cells plated, multiplied by the total number of cells from the previous passage. 
MSC show a similar growth pattern in both types of medium for up to 8 passages. The results represent 
the cumulative expansion rates (mean ± standard deviation) of 3 different MSC cell lines plated at a 
density of 1 x 10
4
cells /cm
2
.   
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Supplementary Figure 4. Analysis of MSC osteogenic differentiation in response to different 
osteogenic inductive conditions. Representative phase contrast images of cells cultured in MesenCult 
osteogenic stimulatory kit (a-b) and MesenCult (c-d), DMEM-F12 (e-f), DMEM-KO (g-h) or DMEM-LG (i-j) 
basal media supplemented with 100 nM dex, 0.2 asc and 10 mM β-GP (from Sigma). Cultured cells were 
seeded at 2 different densities: 0.5x10
4
 (a,c,e,g,i) and 1x10
4
cells/cm
2
 (b,d,f,h,j). Osteogenic differentiation 
of MSCs was assessed by staining for Alkaline Phosphatase (AP) activity after 14 days in differentiation 
medium. Higher levels of AP activity were obtained from the cell at the density 1x10
4
cells/cm
2
 in 
MesenCult osteogenic stimulatory kit medium Images magnification: 400x. 
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